Systematic *in silico* discovery of novel solute carrier-like proteins from proteomes

Gergely Gyimesi* and Matthias A. Hediger*

Membrane Transport Discovery Lab, Department of Nephrology and Hypertension and Department for BioMedical Research, Inselspital, University of Bern, Freiburgstrasse 15, CH-3010 Bern, Switzerland.

*Corresponding authors.
E-mail: gergely.gyimesi@dbmr.unibe.ch (GG), matthias.hediger@ibmm.unibe.ch (MH).

Abstract

Solute carrier (SLC) proteins represent the largest superfamily of transmembrane transporters. While many of them play key biological roles, their systematic analysis has been hampered by their functional and structural heterogeneity. Based on available nomenclature systems, we hypothesized that many as yet unidentified SLC transporters exist in the human genome, which await further systematic analysis. Here, we present criteria for defining "SLC-likeness" to curate a set of "SLC-like" protein families from the Transporter Classification Database (TCDB) and Protein families (Pfam) databases. Computational sequence similarity searches surprisingly identified ~120 more proteins in human with potential SLC-like properties compared to previous annotations. Interestingly, several of these have documented transport activity in the scientific literature. To complete the overview of the "SLC-ome", we present an algorithm to classify SLC-like proteins into protein families, investigating their known functions and evolutionary relationships to similar proteins from 6 other clinically relevant experimental organisms, and pinpoint structural orphans. We envision that our work will serve as a stepping stone for future studies of the biological function and the identification of the natural substrates of the many under-explored SLC transporters, as well as for the development of new therapeutic applications, including strategies for personalized medicine and drug delivery.

Introduction

Membrane transporters and channels are the main entry routes for nutrients, ions, xenobiotics and serve as major exit routes for waste products and metabolites. The solute carrier (SLC) protein superfamily accounts

for over 50% of all transport-related proteins and about 10% of all membrane proteins encoded by the

human genome. With more than 400 annotated members, it is the largest superfamily of membrane

transporter proteins [1,2]. The roles of SLC transporters as cellular gatekeepers, determinants of nutrient

homeostasis and facilitators of drug metabolism and drug targeting has recently been revisited [3]. Around

~50% of currently annotated SLCs are predicted to be associated with human disease phenotypes and many

SLCs are considered to represent promising drug targets or drug delivery systems or to affect drug ADMET

(absorption, distribution, metabolism, extrusion, toxicity). It has recently become evident that the SLC

superfamily offers an enormous unexplored therapeutic treasure. But while the list of approved drugs that

target transporter proteins is increasing, many promising SLCs still remain unexplored, uncharacterized and

underrepresented in the literature.

The SLC nomenclature system has traditionally been used to classify mammalian secondary active and

facilitative transporters, including exchangers and antiporters, into families based on sequence identity per

enquiry by the Human Gene Nomenclature Committee (HGNC) starting in the early 1990s [1]. Originally, SLCs

assignments have been made for all membrane transport proteins that are not channels, ATP-driven pumps,

aquaporins, porins of the outer mitochondrial membrane or ATP-binding cassette (ABC) transporters, while

usually having multiple transmembrane spanning segments and exhibiting transmembrane transport of a

solute, or showing homology to membrane proteins having such features. Due to this construction, the SLC

superfamily is structurally and functionally highly heterogeneous and thus most likely evolutionarily

polyphyletic in origin. Because of these properties and the lack of common sequence patterns in the

different SLC transporters, it has been difficult to assess how many SLC transporters exist in the human

genome or which proteins could be predicted as SLC transporters. Proteins were typically added to the SLC

system on a case-by-case basis. However, in view of recent requests to add new members into the SLC

nomenclature, we suspected that the SLC system might be incomplete.

Despite their heterogeneity, SLC transporters seem to share common properties that probably were

evolutionarily selected based on their suitability as facilitative transporters, secondary active transporters or

exchangers. A remarkable property is that they generally have a symmetric inverted repeat architecture,

which can be observed based on the available structures [4] and can sometimes also be detected at the

sequence level [5,6]. Another important aspect is that the currently well-studied SLC transporters seem to

follow an alternating access mechanism, meaning that the substrate-binding site is exposed on either one or

the other side of the membrane, but not on both sides simultaneously [7,8]. Consequences of these

properties are that SLC transporters typically contain many transmembrane helices (TMHs), and functionally

exhibit saturable transport activity. In addition, most but not all SLC carriers transport water-soluble small

molecules. These properties could be used as criteria to identify additional SLC transporter proteins.

In fact, there have been earlier attempts to gather additional SLCs from the human genome [9–11], as well

as to classify them using automatic methods [12,13]. In this regard, one study [9] used BLAST searches to

find SLC transporters that have local sequence similarities and found that 15 of the known SLC families fall

into 4 phylogenetic clusters, which were termed α, β, γ, and δ groups. In addition, they have found 19

sequences that have previously not been described as SLCs. A later study [12] used a more sensitive HMM-

HMM (hidden Markov-model) comparison-based method to identify locally similar regions in known SLC

proteins. Visualization of the similarity network revealed visible protein clusters that correlated with existing

SLC families. In addition, they identified two unannotated protein sequences that showed similarity to

existing SLC proteins. A common limitation of these studies, however, is that they only searched for proteins

that were similar to proteins already annotated as human SLC transporters. Nevertheless, these efforts using

sequence similarity-based approaches have highlighted that there are additional as yet unannotated SLC

transporters in human protein databases.

In our current study, we aimed to identify missing SLC transporters that may differ from those currently

annotated in human. To do this, we turned to sequence databases and annotation systems that are

phylogenetically broader and not limited to human proteins, and we developed criteria to define "SLC-like"

proteins. Our method is thus more complete and general than previous approaches and tackles the task of

identifying SLC transporters starting from first principles. For this reason, we turned to the Transporter

Classification DataBase (TCDB) to enable the extraction of missing "SLC-like" proteins.

The Transporter Classification DataBase (TCDB) is an alternative classification system that was created in the

1990s in parallel to the SLC nomenclature series [14,15]. It collects transport-related membrane proteins,

including membrane receptors, transporters, ion channels, and membrane-anchored enzymes from all

kingdoms of life, with a particular focus on proteins from lower organisms. The proteins in the TCDB are

organized hierarchically into subfamilies, families and superfamilies based on phylogenetic and functional

considerations, and each member in the database is given a five-segmented TC# similar to the EC# that is

used for enzyme classification. In addition, a brief description is provided for each family that introduces

identified members and contains links to the most important relevant papers.

However, the TCDB dataset is not directly applicable for creating an overview of the collection of SLC

transporters encoded in the human genome (the human SLC-ome). One of the reasons is that the TCDB is set

up as a "representative database", which means that it only contains certain representative sequences from

each family. In addition, there is no particular focus on human proteins, and in fact several annotated human

SLC transporters are not present in the database.

It also seems problematic to consider all proteins in the TCDB that are annotated as part of the secondary

transporter superfamily TC# 2.A as being SLC-like. Indeed, many of the TCDB families annotated as part of

TC# 2.A exhibit structural or sequence features that do not match the characteristics of existing SLCs.

Examples of this are the Trk K^+ transporters (#2.A.38), which display an ion-channel like structural fold [16],

the GUP glycerol uptake proteins (#2.A.50), which exhibit enzymatic activity based on follow-up studies [17],

and the Twin Arginine Targeting (Tat) family (#2.A.64), which are actually protein secretion complexes

[18,19]. Since none of these families correspond to structural or functional characteristics of currently known

SLC transporters, it is likely that not all proteins annotated under the TC# 2.A superfamily are "SLC-like".

Thus, while the TCDB could be a rich source of information for finding new transporters, it is clear that the

perception of what a "transporter" should be according to TCDB does not always correspond to the typical

properties of well-characterized SLC proteins. Additional filtering of TCDB data is therefore necessary.

As part of the TransportDB project, there were parallel efforts to collect secondary transporters from human

and several other organisms [20–22]. Within the TransportDB project, the authors have built an automatic

transporter annotation pipeline (TransAAP), which relies on BLAST searches, the Clusters of Orthologous

Groups (COG) database [23], "selected HMMs for transporter protein families" [22] from the TIGRfam and

Pfam databases [24,25] and hydropathy predictions of TMHMM [26]. This pipeline was used as a

semiautomatic tool to annotate transporter-like proteins from the NCBI RefSeq database. However, based

on the currently available TransportDB website, the resulting protein hits are neither linked to protein

annotation databases, such as UniProt [27], nor are their official gene symbols or SLC names displayed.

Therefore, no correlation with the existing SLC nomenclature is provided, and it is not trivial to say whether

or not an existing SLC protein is included in the database.

We would also like to mention the Protein families (Pfam) database [28], which aims to maintain a curated

set of protein families, often represented by functional domains. Notably, Pfam provides curated HMMs for

each Pfam family to facilitate sequence similarity searches for the occurrence of those domains. In addition,

Pfam groups protein families into higher-order groups called clans. Pfam clans contain evolutionarily related

families whose relationships are supported either by sequence similarity, structural similarity or other

orthogonal biological evidence [29]. While many known Pfam models correspond to the functional regions of

known SLC transporters, Pfam neither attaches special importance to transport-related domains nor to

membrane-spanning domains. For this reason, while the Pfam database could be a rich source of

information about transporters, extracting Pfam families that encode transporter-like domains is non-trivial.

Therefore, there is a clear need in the field to define the criteria of "SLC-likeness" and to identify and classify

all proteins in humans and other species that exhibit "SLC-likeness". Thus, in our work, we interpret the term

"SLC-likeness" by defining the essential criteria for it, and we carry out an exhaustive search for proteins that

potentially meet these criteria, both with manual curation of datasets and with automatic sequence

similarity-based approaches.

Results

Elaboration of criteria for "SLC-likeness"

Since the TCDB takes a very inclusive approach to collecting membrane transport-related proteins from a broad range of biological organisms, we have selected it as the source database for our endeavors. However, as outlined in the introduction, selecting SLC-like proteins from the TCDB is non-trivial. Therefore, we have introduced a set of criteria based on current knowledge of SLC transporters in order to select SLC-like protein families from the TCDB. We believe that these criteria represent the most important properties of currently known SLC transporters. The criteria used to infer SLC-likeness were as follows.

(1) Structure of the protein should be α-helical, with at least three transmembrane helices (TMHs). Proteins with a β-barrel architecture, mostly β-structure proteins, membrane-anchored proteins, cyclic peptides and proteins consisting only of soluble domains (based on predictions or structural data) were excluded.

(2) The size of the transported substrate should fall within the small-molecule range (i.e. oligopeptides might be accepted as substrates but protein secretion systems are excluded). Also excluded are DNA-, RNA- and polysaccharide-transporting systems.

(3) Proteins with a channel-like mechanism were excluded, except in some rare cases. In particular, holins, toxins and other pore-forming proteins, and proteins bearing similarity to them, have been excluded.

(4) Nucleotide-driven transporters (e.g. ATP-binding cassette/ABC families) were excluded.

(5) Receptors that trigger endocytosis upon substrate binding were excluded. Only receptors were included where the receptor protein itself mediates the translocation of the substrate through the membrane, or the insertion of the substrate in the membrane, if that is its final location.

(6) Proteins with enzymatic activity, or similarity to known enzymes were excluded. In some cases, where the protein was believed to contain both a transport domain and a soluble enzyme domain, the proteins have been included.

(7) Proteins where transport activity was used as a synonym for trafficking (i.e. protein or vesicle

translocation within the cell) but otherwise seemingly having no small-molecule transmembrane

transport activity were excluded. On this basis, chaperones and other proteins helping the

insertion of nascent proteins into a cellular membrane were also excluded.

(8) For some (mostly putative) transporter families, TCDB does not give an explanation why the

proteins would be considered as transporters. Families with no resemblance to known

transporters and no indication or argument as to why they would be transporters were

excluded.

We must emphasize that for specific proteins or protein families, the verification of some of the criteria for

SLC-likeness as described above requires extensive and detailed information about the nature of the

transport phenomenon. For example, deciding whether the substrate is a small molecule requires the

identification of the transported solute, while ruling out a channel-like mechanism requires extensive

information about the transport mechanism itself. However, due to missing information, these criteria could

not always be verified while filtering the TCDB for "SLC-like" protein families. In certain cases, even the

identity of the protein that performs the actual membrane translocation within a transporter complex can

be unclear. For similar reasons, the historical discrepancy that the naming and classification of a

gene/protein generally precludes the detailed analysis of its structure and function has also caused the

currently known ("classic") SLC nomenclature to contain transport proteins with a channel-like mechanism

(e.g., the SLC41 family), single TMH (SLC27 family) as well as auxiliary proteins to actual transporters (SLC3

family). Some of these classic SLC families have been included in our selection in order to provide

consistency with the existing SLC nomenclature despite the fact that they do not meet some of our criteria

for SLC-likeness. Nevertheless, we believe that our criteria are broad enough to allow the identification of all

putative SLC-like transporters, while also being specific enough to distinguish them from other well-known,

non transport-related transmembrane protein families. Our criteria enabled us to initiate, for the first time,

an attempt to set up guidelines defining SLC-likeness, in the sense that explicit criteria are established to

disambiguate "transmembrane solute transport" and distinguish from other related membrane protein

activities such as channel-like transport, receptor-mediated endocytosis or protein secretion. In our current

study, we designate proteins and protein families that potentially meet the above criteria as "SLC-like".

Search for novel "SLC-like" proteins

The above-mentioned criteria were applied to manually select protein families in the TCDB that either fulfill

or can potentially fulfill the criteria for SLC-likeness based on the description of each third-level family from

the TCDB database. Throughout this manuscript, we use the term "TCDB family" to refer to third-level

groupings in the classification hierarchy (i.e. TC# x.y.z), while "subfamily" and "superfamily" refer to fourth-

level (TC# x.y.z.w) and second-level (TC# x.y) classes, respectively. In the work presented herein, we have

analyzed superfamilies TC# 1.A, 2.A, 9.A and 9.B, as well as the families and in certain cases the subfamilies

within them (see Table 1).

Table 1. Families and subfamilies examined from the TCDB for SLC-like proteins. Superfamilies marked in

boldface have been analyzed. The superfamily #1.A was examined since several existing SLC families are

classified here, while superfamily #2.A was expected to contain most known SLC proteins. Superfamilies #9.A

and #9.B were also examined. Total number of families and subfamilies in the first-level classes are indicated

in parentheses. Numbers show the total number of level 3 families and level 4 subfamilies in each

superfamily, as well as those found to be "SLC-like" (see text).

TCDB superfamilies	Level 3 families (TC# x.y.z)			Level 4 subfamilies (TC# x.y.z.w)		
	Total	Total examined	Found to be "SLC-like"	Total	Total examined	Found to be "SLC-like"
1 – Channels/Pores	(556)			(997)		
1.A – α-Type Channels		**112**	**7**		**321**	**17**
2 – Electrochemical Potential-driven Transporters	(178)			(561)		
2.A – Porters (uniporters, symporters, antiporters)		**129**	**114**		**556**	**501**
3 – Primary Active Transporters	(47)			(250)		
4 – Group Translocators	(18)			(36)		
5 – Transmembrane Electron Carriers	(17)			(42)		
8 – Accessory Factors Involved in Transport	(163)			(252)		
9 – Incompletely Characterized Transport Systems	(388)			(657)		

9.A – Recognized Transporters of Unknown Biochemical Mechanism		69	20		122	37
9.B – Putative Transport Proteins		306	24		535	43
Total:	(1367)			(2795)		
		616	166		1534	600

It was a significant curation effort to manually assess the 1534 subfamilies within 616 families in the above-

mentioned superfamilies of the TCDB, which were expected to contain SLC transporter-like proteins (Table

1). To streamline our curation efforts, we have also expanded our analysis to Pfam protein families. To this

end, we used HMMER [30] to search for all Pfam models in the sequences of all TCDB members within the

four superfamilies analyzed, as shown in Table 1. The resulting Pfam families found in TCDB sequences were

manually analyzed in tandem with the TCDB families and subfamilies in which they occur whether they also

meet the criteria for SLC-likeness as defined above. The SLC-likeness criteria have been assessed according to

the following guidelines:

• As an inclusive approach, we mainly searched for information that can be used to exclude

(sub)families based on one or more criteria. Missing information (e.g. about transport mechanism,

structure, potential other functions, exact chemical identity of substrate) was not interpreted as a

reason for exclusion, unless it could be replaced by predictions (see below). Therefore, we strived to

include (sub)families in our list that potentially fulfill the criteria for being SLC-like.

• When a (sub)family could be excluded from being SLC-like based on one criterion, the remaining

criteria were not assessed.

• The functional criteria were assessed based on information presented on the TCDB web site in the

family description text and in the description of certain individual members, where this was present,

as well as in the textual descriptions of Pfam families. Families that claim their members to be

"channels" in their descriptions were assumed to function with a channel-like mechanism and were

therefore excluded, unless there was evidence for saturable transport or alternating access

mechanism for certain members. TCDB and Pfam families showing similarity to other transporter

families, either as mentioned in the family descriptions in text or *via* SCOOP-similarity [31], have

been chosen to potentially fulfill the functional criteria, unless specific functional annotations

indicated otherwise.

- 222   The criterion about the size of the substrate was judged based on the known or putative substrate

223   according to TCDB family descriptions. The assumption that certain proteins are transporters,

224   whether based on experimental observations or purely on prediction, always entails the presence of

225   either a tested or an assumed class of substrates. Families where no indication was available why

226   they would function as transporters were thus excluded for the moment until further information on

227   their function becomes available.

- 228   The structural criterion was assessed based on the "number of transmembrane segments"

annotations in the TCDB for each protein. (Sub)families where their TCDB descriptions mentioned a

β-barrel structure or relationship with such proteins were excluded. Care was taken to identify

outliers, i.e. proteins with less TMHs as the functional unit, which could potentially be fragments,

and proteins with extra TMHs in addition to the functional core. In this regard, we based our

decision on Pfam models conserved in the (sub)family and the number of THMs the model spans

according to predictions at the Pfam web site for the most characterized members of the

(sub)family. For certain Pfam families, structures and annotations from the Protein Data Bank (PDB)

linked with the family on the Pfam web site were used to decide whether or not the Pfam model

encodes soluble proteins, provided that the family model has sufficient coverage by the structure

available.

- 239   In some TCDB families with multicomponent transport systems, the membrane-spanning core

components were identified by the presence of conserved Pfam models in all members of the

family. Whether Pfam domains were membrane-spanning was deduced by their descriptions at the

Pfam web site and Pfam prediction of TMHs. The TCDB description of the family also helped in

deciding which components were essential and membrane-spanning. If multiple such Pfam models

were found, the proteins were assumed to function as an obligate heteromultimer, and such

proteins were considered as a single entity to assess the overall number of TMHs for the structural

criterion.

Strikingly, of the 1534 subfamilies examined, only 600 in 166 families were found to be SLC-like according to

our criteria. In particular, of the 556 subfamilies within superfamily TC# 2.A ("porters"), only 501 appeared to

meet our selection criteria. This underlines once more that the term "porter" in relation to solute transport

is ambiguous in this field and a clearer definition of the perception of a solute transporter protein is needed.

Our curation efforts also yielded 209 Pfam families bearing SLC-like properties, which likely contain the

membrane-spanning regions of SLC-like proteins selected from the 336 Pfam families present in total in the

TCDB sequences analyzed. Special care has been taken to consistently include or exclude TCDB (sub)families

and their corresponding Pfam family, if applicable, from our selection. Notably, many of those Pfam families

that have been excluded represented soluble structural or regulatory domains. Following our initial round of

selection, we took advantage of clan groupings in Pfam and extended our selection efforts to analyze Pfam

families belonging to the same clan as the selected 209 SLC-like Pfam families. This was based on the

observation that many SLC-like transporter families in Pfam appear grouped into clans, so that members of

these clans might represent SLC-like transporters themselves. As noted before, Pfam clans represent

remotely related protein families, and while protein function is not always conserved across different

families within a Pfam clan, the inspection of these families whether they meet our SLC-likeness criteria is

validated by their relatedness or similarity to SLC-like families. Such a "clan expansion" procedure resulted in

12 additional Pfam families that are evolutionarily related to SLC-like protein families, of which 8 Pfam

families potentially meet our criteria as SLC-like, as evaluated according to the guidelines and criteria above.

Interestingly, these 8 SLC-like Pfam families currently have no representatives with a modest score (bit score

> 25) in the TCDB, while 4 of the 8 families are annotated in Pfam as domains of unknown function (DUF).

Thus, a total of 217 SLC-like Pfam families were identified in our search (see S1 Table).

We would like to note that our selection of SLC-like TCDB families and subfamilies as well as Pfam families is

limited by the availability of information on less characterized protein families and may therefore need to be

revised as more information becomes available. Our criteria are objective, however, and can easily be used

to revise the decision as to whether a particular family is SLC-like in the light of new information.

As a next step, we wanted to know whether the selected families either from the TCDB or from Pfam have

representatives in the proteomes of human and other clinically relevant organisms. For this analysis, we

selected 7 organisms due to their clinical relevance or scientific utility (*Homo sapiens*, *Rattus norvegicus*,

Mus musculus, *Gallus gallus*, *Danio rerio*, *Drosophila melanogaster*, *Caenorhabditis elegans*), for which we

downloaded all sequences from the UniProt database [27], including Swiss-Prot (curated) and TrEMBL

(predicted) [32] entries. Sequences of proteins in the TCDB have been aligned within each SLC-like family and

subfamily and the alignments converted to HMMs for sensitive sequence similarity searches (see Methods).

In addition, HMMs of SLC-like Pfam families were downloaded from the Pfam database. HMM-based

similarity searches were then performed on the sequences downloaded for the 7 organisms to find proteins

similar to any of the SLC-like TCDB families or subfamilies, or SLC-like Pfam domains, followed by the

clustering of sequence fragments to arrive at one representative protein sequence per gene (see Methods).

The results of our search for SLC-like proteins are summarized in numbers in Table 2. Briefly, 59-67 of the

166 TCDB families have representatives in the 7 organisms (66 in human), and the organisms seem to

contain 434-673 SLC-like proteins (549 in human). In total, 3733 proteins have been found in the 7 organisms

studied. Notably, the number of SLC-like transporters found in human in our search is ~130 higher than

previously reported [2], indicating that the human SLC-ome may be significantly larger than previously

thought.

Table 2. Results of the initial search for "SLC-like" proteins. The search was performed using HMM-based

sequence similarity analysis based on selected families and subfamilies from the TCDB, as well as selected

Pfam models that likely encode transmembrane domains of "SLC-like" transporters (see text for details). The

table shows the number of families, subfamilies from the TCDB and the number of Pfam models that had

representative sequences in each organism. In addition, the initial number of "SLC-like" proteins found is

shown.

Species	Level 3 families (TC# x.y.z)	Level 4 subfamilies (TC# x.y.z.w)	Pfam models	Proteins
Human (*H. sapiens*)	66	308	79	549
Mouse (*M. musculus*)	67	314	79	532
Rat (*R. norvegicus*)	67	316	79	537
Zebrafish (*D. rerio*)	65	312	80	673
Chicken (*G. gallus*)	63	305	77	473
Fruitfly (*D. melanogaster*)	60	273	66	434
Roundworm (*C. elegans*)	59	283	69	535

After arriving at this initial set of SLC-like proteins, we proceeded by a performing a first round of sanitization

based on human proteins. First, we manually investigated the UniProt records of all human hits that are non

Swiss-Prot-validated sequences, which revealed that 19 out of 23 are likely non-human or fragment

sequences (S2 Table). After excluding these, we investigated the number of helical transmembrane (TM)

segments annotated in UniProt for 144 of all remaining 530 human hits that do not correspond to classic SLC

transporters (families SLC1-SLC52). In total, 17 of these proteins, showing similarity to 8 different TCDB

families, contained less than 3 TMHs based on UniProt annotations and thus did not satisfy our structural

criterion (1). These proteins have been investigated individually based on their coverage of HMMs used in

the search and the location of TMHs according to UniProt annotations in other SLC-like proteins covering the

same HMMs, as well as available literature on oligomeric state and function. This way, we have retained 8

sequences where the functional unit contains 3 or more TMHs, or the protein spans at least 3 TMHs based

on HMM coverage, or for other reasons (see S4 Table). These proteins have been included in Table 3 and S4

Table. In contrast, 10 of the 17 proteins seemed to cover regions of HMMs where other members did not

seem to contain TMHs, while in addition containing less than 3 TMHs or known non-transporter TM

domains. Notably, certain Pfam models seem to cover both TM and non-TM domains, and several TCDB

families and their corresponding HMMs encode multi-domain proteins, leading to hits that show similarity to

the model in the non-TM region, but not in the TM region that would be crucial for SLC-likeness. These 10

proteins have been excluded from further analyses and included in S2 Table. Furthermore, initial SLC-like hits

that only match with such non-TM regions of these HMMs (#2.A.19.3 positions 250-725, #9.B.64.1 positions

above 200, "OST3_OST6" positions below 200, "RBP_receptor" positions above 400) in all other organisms

have also been excluded from further analyses. Thus, in this initial sanitization step, 29 human proteins, as

well as 8, 10, 2, 9, and 6 proteins from *M. musculus*, *R. norvegicus*, *C. elegans*, *D. rerio*, and *G. gallus*,

respectively, have been excluded, leaving a remaining 3669 proteins for further analysis, including 520 from

human.

As a next step, we proceeded by attempting to classify the remaining proteins into protein families, followed

by manual database and literature searches focused on novel human proteins, as detailed below.

Classification into families

As mentioned in the introduction, SLC carriers are likely of polyphyletic origin, and individual families can be

so diverse that even sensitive sequence similarity-based methods may have difficulties grouping related SLCs

[12]. In our experience, multiple sequence alignment-based methods were not able to cluster the identified

SLC-like sequences and to reproduce known SLC families, so we devised a custom method for clustering

distantly related sequences into proteins families based on the introduction of "HMM fingerprints". An

HMM fingerprint is a mathematical vector of numbers assigned to a protein sequence, where the numbers

represent the similarity scores of that protein sequence against each of the TCDB families, subfamilies and

Pfam families that we have selected to be SLC-like. Thus, two protein sequences that show a similar pattern

in their HMM fingerprints indicate their similarity. The usefulness of an HMM fingerprint depends on a

meaningful definition of HMMs used in the fingerprint, whereby we capitalize on the evolutionary principle

in the construction of TCDB families, subfamilies as well as Pfam families. Nevertheless, our goal was not to

reconstruct the evolutionary history of a set of proteins, but to group proteins that share similar sequence

features. However, due to the transitivity of homology and since similarity to a group of proteins suggests

homology, clusters derived using HMM fingerprinting are likely to contain homologous proteins.

The HMM fingerprint-based classification of the SLC-like proteins found in our search yielded 102 protein

families in total, 94 of which had representatives in human (Fig 1). For existing SLC transporters, the

generated families corresponded well to classical SLC families. Interestingly, outlier proteins were found in

several families, which did not cluster with their families at the threshold we used. Examples include SLC5A7,

SLC10A7, SLC25A46, SLC30A9, SLC39A9, MPDU1/SLC66A5 as well as the SLC9B family and SLC35 subfamilies.

This shows that the HMM fingerprints, and thus likely the sequences of these outlier proteins diverge from

those of other members of their families, and the sequences of subfamilies seem to diverge in certain cases.

Several classic SLC families also clustered together, such as SLC32-SLC36-SLC38, SLC2-SLC22, and SLC17-

SLC18-SLC37 proteins, likely due to their high sequence similarity. To ensure optimal correlation with the

preexisting classification of classic SLC proteins, we have introduced split and join constraints to keep 1)

closely related families separated, 2) outlier proteins merged with their families and 3) heterogenous

families merged (see Methods). These constraints did not affect the classification of novel SLC-like proteins.

The number of families proposed by our method is somewhat dependent on the threshold of clustering

used. Raising it to 0.8 lowers the number of families to 98 (90 in human), joining families SLC58-pSLC.OSTC,

SLC8-SLC24, SLC45-SLC59, and SLC65-pSLC.Dispatched, as well as pSLC.TSPO to a 2-membered subfamily of

unannotated proteins from *D. rerio*. Since our clustering method is based on shared HMMs, these families

are likely related. Indeed, SLC8 and SLC24 proteins constitute a superfamily of Na^+/Ca^{2+} antiporters [33],

while NPC1/SLC65A1 and Dispatched proteins share structural similarity [34]. Lowering the clustering

threshold to 0.6 generates 107 families (96 in human), splitting the pSLC.TMEM41-64 family to the TMEM41

and TMEM64 subfamilies, the MFSD3 proteins off the SLC33 family, an unannotated protein from *D.*

melanogaster off the XK protein family, as well as splitting an unannotated protein family from *D.*

melanogaster into two subfamilies.

Figure 1. Dendrogram of human SLC-like protein families based on HMM fingerprint-based clustering.

Classic and newly incorporated SLC families are shown with colors. Since SLC proteins are polyphyletic, which

manifests itself in mathematically orthogonal HMM fingerprints that cannot be further clustered, the

dendrogram does not join into a single branch. Branch lengths have been transformed for better visibility

(see Methods).

Our analysis revealed 42 new proteins families in total in human, containing proteins that have not yet been

annotated as SLCs. Interestingly, our search has also found new proteins that clustered into existing SLC

families (Table 3, S4 Table).

Table 3. Novel SLC-like proteins. The table shows SLC-like human proteins from our search that are not in

the classic group of SLCs (SLC1-52 families). The most similar (highest-scoring) TCDB family/subfamily and

Pfam family are shown, as well as the most similar (highest-scoring) protein with structural information

based on the pdb70 dataset (see Methods). Substrate information, where available, was retrieved from

373 available literature. Based on our search, SLC families SLC53-66 have recently been incorporated into the

374 nomenclature in collaboration with the HUGO/HGNC. Proteins marked with a single asterisk are included

375 due to sequence similarity but may have functions other than transporter. Proteins marked with double

376 asterisks might have a channel-like transport mechanism. For additional details, see S4 Table.

Gene symbol	TCDB family	Pfam family	Protein name	Structural fold	Substrates
SLC18 family					
MFSD8	2.A.1.2	MFS_1	Major facilitator superfamily domain-containing protein 8	MFS	orphan
MFSD9	2.A.1.2	MFS_1	Major facilitator superfamily domain-containing protein 9	MFS	orphan
MFSD10	2.A.1.2	MFS_1	Major facilitator superfamily domain-containing protein 10	MFS	indomethacin
MFSD14A	2.A.1.2	MFS_1	Hippocampus abundant transcript 1 protein	MFS	orphan
MFSD14B	2.A.1.2	MFS_1	Hippocampus abundant transcript-like protein 1	MFS	orphan
MFSD14C	2.A.1.2	MFS_1	Hippocampus abundant transcript-like protein 2	MFS	orphan
SLC22A18	2.A.1.2	MFS_1	Solute carrier family 22 member 18	MFS	orphan
SLC22 family					
SV2A (SLC22B1)	2.A.1.22	Sugar_tr	Synaptic vesicle glycoprotein 2A	MFS	galactose; also binds levetiracetam, seletracetam, brivaracetam.
SV2B (SLC22B2)	2.A.1.22	MFS_1	Synaptic vesicle glycoprotein 2B	MFS	orphan
SV2C (SLC22B3)	2.A.1.22	MFS_1	Synaptic vesicle glycoprotein 2C	MFS	orphan
SVOP (SLC22B4)	2.A.1.82	Sugar_tr	Synaptic vesicle 2-related protein	MFS	nicotinate; binds nucleotides in the TM region: 8-azido-ATP; ATP; GTP; TTP; CTP; NAD
SVOPL (SLC22B5)	2.A.1.82	MFS_1	Putative transporter SVOPL	MFS	orphan
SLC33 family					
MFSD3	2.A.1.57	Acatn	Major facilitator superfamily domain-containing protein 3	MFS	orphan
SLC35 family					
TMEM241	2.A.7.13	TPT	Transmembrane protein 241	NST	orphan
SLC42 family					
RHCE*	1.A.11.4	Ammonium_transp	Blood group Rh(CE) polypeptide	Amt	orphan
RHD*	1.A.11.4	Ammonium_transp	Blood group Rh(D) polypeptide	Amt	orphan
SLC51A family					
TMEM184A*	2.A.82	Solute_trans_a	Transmembrane protein 184A		orphan
TMEM184B	2.A.82	Solute_trans_a	Transmembrane protein 184B		orphan
TMEM184C	2.A.82	Solute_trans_a	Transmembrane protein 184C		orphan
SLC53 family					
XPR1 (SLC53A1)	2.A.94	EXS	Xenotropic and polytropic retrovirus receptor 1		phosphate
SLC54 family					
MPC1 (SLC54A1)	2.A.105	MPC	Mitochondrial pyruvate carrier 1		pyruvate
MPC2 (SLC54A2)	2.A.105	MPC	Mitochondrial pyruvate carrier 2		pyruvate
MPC1L (SLC54A3)	2.A.105	MPC	Mitochondrial pyruvate carrier 1-like protein		pyruvate
SLC55 family					
LETM1 (SLC55A1)	2.A.97	LETM1	Mitochondrial proton/calcium exchanger protein		K^+/H^+
LETM2 (SLC55A2)	2.A.97	LETM1	LETM1 domain-containing protein LETM2, mitochondrial		orphan
LETMD1 (SLC55A3)	2.A.97	LETM1	LETM1 domain-containing protein 1		orphan
SLC56 family					
SFXN1 (SLC56A1)	2.A.54	Mtc	Sideroflexin-1		L-serine

SFXN2 (SLC56A2)	2.A.54	Mtc	Sideroflexin-2		orphan
SFXN3 (SLC56A3)	2.A.54	Mtc	Sideroflexin-3		orphan
SFXN4 (SLC56A4)	2.A.54	Mtc	Sideroflexin-4		orphan
SFXN5 (SLC56A5)	2.A.54	Mtc	Sideroflexin-5		orphan
SLC57 family					
NIPA1 (SLC57A1)	2.A.7.25	Mg_trans_NIPA	Magnesium transporter NIPA1	NST	Mg^{2+}; to a lesser extent Sr^{2+}, Fe^{2+}, Co^{2+}
NIPA2 (SLC57A2)	2.A.7.25	Mg_trans_NIPA	Magnesium transporter NIPA2	NST	very specific to Mg^{2+}
NIPAL1 (SLC57A3)	2.A.7.25	Mg_trans_NIPA	Magnesium transporter NIPA3	NST	Mg^{2+}, Sr^{2+}, Ba^{2+}, Fe^{2+}, Cu^{2+}
NIPAL2 (SLC57A4)	2.A.7.25	Mg_trans_NIPA	NIPA-like protein 2	NST	Mg^{2+}, Sr^{2+}, Ba^{2+}
NIPAL3 (SLC57A5)	2.A.7.25	Mg_trans_NIPA	NIPA-like protein 3	NST	orphan
NIPAL4 (SLC57A6)	2.A.7.25	Mg_trans_NIPA	Magnesium transporter NIPA4	NST	orphan
SLC58 family					
MAGT1** (SLC58A1)	1.A.76.1	OST3_OST6	Magnesium transporter protein 1	MagT	Mg^{2+}
TUSC3 (SLC58A2)	1.A.76.1	OST3_OST6	Tumor suppressor candidate 3	MagT	Mg^{2+}, Fe^{2+}, Cu^{2+}, Mn^{2+}
SLC59 family					
MFSD2A (SLC59A1)	2.A.2.3	MFS_2	Sodium-dependent lysophosphatidylcholine symporter 1	MFS	LPC DHA (docosahexaenoic acid); LPC palmitate; also binds TopFluor LPE
MFSD2B (SLC59A2)	2.A.2.3	MFS_2	Major facilitator superfamily domain-containing protein 2B	MFS	sphingosine-1-phosphate (S1P)
MFSD12	2.A.2.7	MFS_2	Major facilitator superfamily domain-containing protein 12	MFS	cysteine
MFSD13A	2.A.2.3	MFS_2	Transmembrane protein 180	MFS	orphan
SLC60 family					
MFSD4A (SLC60A1)	2.A.1.7	MFS_1	Major facilitator superfamily domain-containing protein 4A	MFS	orphan
MFSD4B (SLC60A2)	2.A.1.7	MFS_1	Sodium-dependent glucose transporter 1	MFS	alpha-methyl-d-glucopyranoside, D-glucose, urea
SLC61 family					
MFSD5 (SLC61A1)	2.A.1.40	MFS_5	Molybdate-anion transporter	MFS	molybdate
SLC62 family					
ANKH (SLC62A1)	2.A.66.9	ANKH	Progressive ankylosis protein homolog	MATE	pyrophosphate
SLC63 family					
SPNS1 (SLC63A1)	2.A.1.49	MFS_1	Protein spinster homolog 1	MFS	orphan
SPNS2 (SLC63A2)	2.A.1.49	MFS_1	Protein spinster homolog 2	MFS	sphingosine-1-phosphate (S1P), phosphorylated Fingolimod (FTY720-P); dihydrosphingosine-1-phosphate (DH-S1P); phyto-S1P, C17-S1P
SPNS3 (SLC63A3)	2.A.1.49	MFS_1	Protein spinster homolog 3	MFS	orphan
SLC64 family					
TMEM165 (SLC64A1)	2.A.106.2	UPF0016	Transmembrane protein 165		Ca^{2+}/H^{+}, Mn^{2+}
SLC65 family					
NPC1 (SLC65A1)	2.A.6.6	Patched	NPC intracellular cholesterol transporter 1	RND	cholesterol
NPC1L1 (SLC65A2)	2.A.6.6	Patched	NPC1-like intracellular cholesterol transporter 1	RND	cholesterol
PTCH1	2.A.6.6	Patched	Protein patched homolog 1	RND	cholesterol
PTCH2	2.A.6.6	Patched	Protein patched homolog 2	RND	likely cholesterol based on functional similarity to PTCH1
PTCHD1	2.A.6.6	Patched	Patched domain-containing protein 1	RND	orphan
PTCHD3	2.A.6.6	Patched	Patched domain-containing protein 3	RND	orphan
PTCHD4	2.A.6.6	Patched	Patched domain-containing protein 4	RND	orphan

SCAP*	2.A.6.6	Patched	Sterol regulatory element-binding protein cleavage-activating protein	RND (half)	cholesterol, 25-hydroxycholesterol
HMGCR*	2.A.6.6	Patched	3-hydroxy-3-methylglutaryl-coenzyme A reductase	RND (half)	probably sterols
SLC66 family					
PQLC2 (SLC66A1)	2.A.43.2	PQ-loop	Lysosomal amino acid transporter 1 homolog	SWEET	L-Arg, L-Lys, L-His, L-canavanine, L-ornithine, cysteamine-cysteine mixed disulfide
PQLC1 (SLC66A2)	2.A.43	PQ-loop	PQ-loop repeat-containing protein 1	SWEET	orphan
PQLC3 (SLC66A3)	2.A.43.3	PQ-loop	PQ-loop repeat-containing protein 3	SWEET	orphan
CTNS (SLC66A4)	2.A.43.1	PQ-loop	Cystinosin	SWEET	L-cystine, L-selenocystine, L-cystathionine, H$^+$
MPDU1 (SLC66A5)	2.A.43.3	PQ-loop	Mannose-P-dolichol utilization defect 1 protein	SWEET	orphan
PQLC2L	2.A.43.2	PQ-loop	Putative uncharacterized protein PQLC2L	SWEET	orphan
pSLC.ARV1 family					
ARV1	9.A.19	Arv1	Protein ARV1		orphan
pSLC.Battenin					
CLN3	2.A.57.5	CLN3	Battenin	MFS	orphan
pSLC.CLCN					
CLCN1**	2.A.49.2	Voltage_CLC	Chloride channel protein 1	CLC	channel for chloride, thiocyanate, perchlorate, bromide, nitrate, chlorate, iodide
CLCN2**	2.A.49.2	Voltage_CLC	Chloride channel protein 2	CLC	channel for chloride, bromide, iodide
CLCN3	2.A.49.2	Voltage_CLC	H(+)/Cl(-) exchange transporter 3	CLC	antiport of chloride and H$^+$
CLCN4	2.A.49.2	Voltage_CLC	H(+)/Cl(-) exchange transporter 4	CLC	antiport of chloride and H$^+$, also nitrate, bromide, iodide
CLCN5	2.A.49.2	Voltage_CLC	H(+)/Cl(-) exchange transporter 5	CLC	antiport of chloride and H$^+$, also nitrate, bromide, iodide
CLCN6	2.A.49.3	Voltage_CLC	Chloride transport protein 6	CLC	antiport of chloride and H$^+$, also nitrate, iodide
CLCN7	2.A.49.3	Voltage_CLC	H(+)/Cl(-) exchange transporter 7	CLC	antiport of chloride and H$^+$
CLCNKA**	2.A.49.2	Voltage_CLC	Chloride channel protein ClC-Ka	CLC	channel for chloride, bromide, nitrate, iodide
CLCNKB**	2.A.49.2	Voltage_CLC	Chloride channel protein ClC-Kb	CLC	channel for chloride, bromide, nitrate, iodide
pSLC.CNNM					
CNNM1	1.A.112	DUF21	Metal transporter CNNM1	CorB	orphan
CNNM2	1.A.112	DUF21	Metal transporter CNNM2	CorB	Mg^{2+}, Co^{2+}, Mn^{2+}, Sr^{2+}, Ba^{2+}, Cu^{2+}, Fe^{2+}, Na$^+$
CNNM3	1.A.112	DUF21	Metal transporter CNNM3	CorB	orphan
CNNM4	1.A.112	DUF21	Metal transporter CNNM4	CorB	putatively Mg^{2+}, maybe antiport of Na$^+$
pSLC.CitMHS					
OCA2	2.A.45.2	CitMHS	P protein	AbgT	putatively chloride
pSLC.Dispatched					
DISP1	2.A.6.9	Patched	Protein dispatched homolog 1	RND	hedgehog protein
DISP2	2.A.6.9	Sterol-sensing	Protein dispatched homolog 2	RND	orphan
DISP3	2.A.6	Patched	Protein dispatched homolog 3	RND	putatively cholesterol
pSLC.GPR155					
GPR155	2.A.69.3	Mem_trans	Integral membrane protein GPR155	NhaA	orphan
pSLC.LAPTM					
	2.A.74.1	Mtp	cDNA FLJ61683, moderately similar to Lysosomal-associated multitransmembrane protein		orphan
LAPTM4A	2.A.74.1	Mtp	Lysosomal-associated transmembrane protein 4A	Tspn	thymidine, uridine, multi-drug resistance
LAPTM4B	2.A.74.1	Mtp	Lysosomal-associated transmembrane protein 4B		putatively ceramide, multi-drug resistance
LAPTM5	2.A.74.1	Mtp	Lysosomal-associated transmembrane protein 5	Tspn	orphan
pSLC.LMBR-A					
LMBRD1	9.A.54.1	LMBR1	Probable lysosomal cobalamin transporter		orphan
pSLC.LMBR-B					
LMBR1		LMBR1	Limb region 1 protein homolog		orphan
LMBR1L*	9.A.54.1	LMBR1	Protein LMBR1L		orphan
LMBRD2*	9.A.54.3	LMBR1	LMBR1 domain-containing protein 2		orphan
pSLC.MFSD1					
MFSD1	2.A.1.53	MFS_1	Major facilitator superfamily domain-containing protein 1	MFS	orphan
pSLC.MFSD6					
MFSD6	2.A.1.65	MFS_1_like	Major facilitator superfamily domain-containing protein 6	MFS	putatively sugars
MFSD6L	2.A.1.65	MFS_1_like	Major facilitator superfamily domain-containing protein 6-like	MFS	orphan
pSLC.OSTC					

	1.A.76.2	OST3_OST6	cDNA FLJ52625	MagT	orphan
OSTC	1.A.76.2	OST3_OST6	Oligosaccharyltransferase complex subunit OSTC	MagT	orphan
OSTCL	1.A.76.2	OST3_OST6	Oligosaccharyltransferase complex subunit-like	MagT	orphan
pSLC.RFT1					
RFT1	2.A.66.3	Rft-1	Protein RFT1 homolog	MATE	orphan
pSLC.SIDT					
SIDT1	1.A.79.1	SID-1_RNA_chan	SID1 transmembrane family member 1		cholesterol
SIDT2	1.A.79.1	SID-1_RNA_chan	SID1 transmembrane family member 2		cholesterol
pSLC.STAR					
STARD3	9.B.64	MENTAL	StAR-related lipid transfer protein 3		probably cholesterol
STARD3NL	9.B.64	MENTAL	STARD3 N-terminal-like protein		binds cholesterol
pSLC.STRA					
STRA6	2.A.90.1	RBP_receptor	Receptor for retinol uptake STRA6	STRA6	retinol
pSLC.TMCO3					
TMCO3	2.A.37.1	Na_H_Exchanger	Transmembrane and coiled-coil domain-containing protein 3	NhaA	orphan
pSLC.TMEM14					
TMEM14A	2.A.126.1	Tmemb_14	Transmembrane protein 14A	TMEM14	orphan
TMEM14B	2.A.126.1	Tmemb_14	Transmembrane protein 14B	TMEM14	orphan
TMEM14C	2.A.126.1	Tmemb_14	Transmembrane protein 14C	TMEM14	protoporphyrinogen IX
TMEM14DP	2.A.126.1	Tmemb_14	Transmembrane protein 14DP	TMEM14	
pSLC.TMEM41-64					
TMEM41A	9.B.27.1	SNARE_assoc	Transmembrane protein 41A		orphan
TMEM41B	9.B.27.1	SNARE_assoc	Transmembrane protein 41B		scramblase of cholesterol, phosphatidylserine
TMEM64*	9.B.27.5	SNARE_assoc	Transmembrane protein 64		orphan
pSLC.TMEM104					
TMEM104	2.A.18.10	Aa_trans	Transmembrane protein 104	APC	orphan
pSLC.TMEM144					
TMEM144	2.A.7.8	TMEM144	Transmembrane protein 144	NST	orphan
pSLC.TMEM163					
TMEM163	2.A.4.8	Cation_efflux	Transmembrane protein 163	CDF	Zn^{2+}
pSLC.TMEM205					
TMEM205	9.A.55.1	DUF4149	Transmembrane protein 205		orphan
pSLC.TMEM234					
TMEM234	2.A.7.32	TMEM234	Transmembrane protein 234	NST	orphan
pSLC.TMEM245					
TMEM245	2.A.86	AI-2E_transport	Transmembrane protein 245		orphan
pSLC.TSPO					
TSPO	9.A.24.1	TspO_MBR	Translocator protein	TSPO	protoporphyrin IX, cholesterol
TSPO2	9.A.24.1	TspO_MBR	Translocator protein 2	TSPO	5-aminolevulinic acid
pSLC.UNC93					
MFSD11	2.A.1.58	UNC-93	UNC93-like protein MFSD11	MFS	orphan
UNC93A	2.A.1.58	UNC-93	Protein unc-93 homolog A	MFS	orphan
UNC93B1*	2.A.1.58	UNC-93	Protein unc-93 homolog B1	MFS	orphan
pSLC.XK					
XK	2.A.112.1	XK-related	Membrane transport protein XK	XK	orphan
XKR3	2.A.112.1	XK-related	XK-related protein 3	XK	orphan
XKR4	2.A.112.1	XK-related	XK-related protein 4	XK	phosphatidylserine
XKR5	2.A.112.1	XK-related	XK-related protein 5	XK	orphan
XKR6	2.A.112.1	XK-related	XK-related protein 6	XK	orphan
XKR7	2.A.112.1	XK-related	XK-related protein 7	XK	orphan
XKR8	2.A.112.1	XK-related	XK-related protein 8	XK	phosphatidylserine
XKR9	2.A.112.1	XK-related	XK-related protein 9	XK	phosphatidylserine
XKRX	2.A.112.1	XK-related	XK-related protein 2	XK	orphan

Structural homologues

For polytopic transmembrane proteins, structural similarity can support evolutionary relatedness, while at

the same time evolutionary relatedness can provide a basis for homology-based model building efforts

[35,36]. On the other hand, the lack of predicted similarity to any protein of known structure could pin down

interesting targets for structural biology efforts by highlighting proteins likely belonging to new fold families.

We performed HMM-based searches on the pdb70 database (sequences of the proteins represented in the

Protein Data Bank clustered to 70% sequence identity, see Methods) to assess whether structural

homologues are available for the proteins found. In total, for 79 of the 102 families, at least one similar

protein was found with a corresponding structure in the Protein Data Bank. Importantly, 477 human SLC-like

proteins likely have a homologue whose structure has been solved. On the other hand, 43 human SLC-like

proteins belonging to 19 different families do not seem to have homologues with a known structure and

thus are likely to constitute novel fold families. For the classical SLC proteins, their best-scoring similar

proteins from the pdb70 dataset and the corresponding structural fold families are summarized in S3 Table.

Based on this, it appears that classical SLCs from families SLC34, SLC44, SLC48 and SLC51 are still "structural

orphans".

Detecting remote homology to proteins with a known transporter fold can also support their transporter

function as well as give clues about their transport mechanism. Fold families that are well-characterized and

typically host transporters with an alternating access mechanism encode potential transporter-like

structures. Out of the 18 fold families to which novel SLC-like proteins show similarity to (S4 Table),

representatives of 7 have been observed in various conformational states that hint at an alternating access

mechanism, while for a further 7 fold families, a transport mechanism has been suggested (S4 Table). These

fold families cover 87 of the novel SLC-like transporters, suggesting a possible transporter-like transport

mechanism for these proteins (S4 Table).

Phylogenetic analysis

Model organisms can be useful to study the biological function of various proteins, including solute

transporters. In order to relate the results to human, however, knowledge of orthologous gene pairs is

necessary. To this end, we performed phylogenetic analysis on each family of SLC-like proteins

corresponding to our clustering. In brief, unrooted phylogenetic trees for each SLC-like protein family from

all organisms have been generated and reconciled with the species tree of the 7 organisms in our study to

identify gene duplication and speciation events in their evolutionary histories (see Methods). The resulting

evolutionary trees are deposited in S1 File. Based on these trees, we carried out orthology analysis focusing

on human proteins and the human lineage. The resulting data is presented in Fig 2, showing relationships

between human genes and their orthologs in the other 6 organisms in our study. In addition, gene clusters

are presented that have arisen through gene duplication events in the evolutionary history of the human

lineage, but where the corresponding human genes have likely been lost.

Figure 2. Orthology analysis of SLC-like proteins based on the human lineage. Each line shows a gene

cluster that has evolved through gene duplication events along the human lineage. The human gene in the

cluster, if present, is noted in the text label. Normal grey boxes in each column indicate a 1:1 orthology

relationship between the human gene and a corresponding gene in the organism specified. Dark grey boxes

indicate that the human gene has several orthologs, and light grey boxes indicate that several human genes

share a common ortholog in that organism. White boxes denote no ortholog in the organism specified, while

lines without a human gene name correspond to genes that have been lost in human.

Literature search on newly found SLC-like proteins

As alluded to above, our search was followed by thorough investigation of the available literature to check

whether a description of transport activity for the newly found proteins is available. Surprisingly, our search

has revealed human proteins for which transported substrates are known. These data have been included in

Table 3. While examining the available literature of these proteins, we have also extracted information

related to our criteria for SLC-likeness, especially with a focus on structure, function and transport

mechanism. In total, 53 proteins could be assigned a small-molecule substrate and therefore fulfill our

criterion for substrate size (2), and for a further 6, putative small-molecule substrates have been suggested.

Nevertheless, 74 proteins, while showing sequence similarity to transporters, are still "orphans" with no

indication of a substrate. We have not found any indication in the literature that any of the proteins found in

our search would have nucleoside-driven transport activity, therefore all of these proteins likely also fulfill

our criterion 4. Interestingly, 9 proteins have been found that have described roles other than

transmembrane solute transport, while showing similarity to SLC-like transporter proteins. These proteins

potentially do not fulfill our functional criteria (5, 6, 7), they are marked with an asterisk in Table 3 and the

details are further evaluated in S4 Table. In total, 3669 potentially SLC-like proteins have been found, and

out of the 520 human proteins, 134 proteins that are not classic SLC transporters showed similarity to SLC-

like proteins. Ruling out proteins with suggested other functions and a channel-like mechanism leaves 119

proteins, out of which 79 show similarity to transporters with a proposed transport mechanism, while 47

could be assigned endogenous small-molecule substrates.

Discussion

Our curation and search efforts have revealed a surprising 134 human proteins that are SLC-like but have not

been officially part of the SLC nomenclature before the start of our study. Interestingly, around 30 of them

were addressed in an earlier study and referred to as "atypical SLC transporters" [10,11]. All of these atypical

transporters have also been identified in our study, together with many others, including several that are not

part of the major facilitator superfamily (MFS) or the amino acid-polyamine-cation (APC) transporter

superfamily.

Our HMM fingerprint-based classification method yielded 102 protein families. Interestingly, in order to

reproduce some of the classic SLC families, we had to introduce clustering constraints to artificially split or

merge predicted families. In turn, increasing or decreasing the clustering threshold by 0.1 changes the

number of families to 98 and 107, respectively. Researchers have reported similar problems with the

classification of the highly diverse protein set of the Pfam database [29]. In particular, Finn et al. note that

closely related Pfam families may have artificially high thresholds to prevent them from overlapping, while

divergent families cannot always be covered by a single model [29]. Thus, we believe that however protein

families are shaped, the discovery of evolutionary relationships between them will always be necessary to

define higher-order superfamilies, similarly to Pfam clans [29]. Similarly, the analysis of the evolutionary

relationship of proteins within each family is equally validated, and several classic SLC families indeed

contain established subfamilies based on sequence and/or functional comparisons [37–40]. In this regard,

we believe that our work provides correlation between transporter proteins in the studied organisms with

the hierarchy of families and subfamilies in the TCDB database on the one hand, and a scale-free framework

for protein grouping and classification through HMM fingerprints on the other hand. Still, more work is

needed to examine the evolutionary relatedness of different SLC-like families using more robust

phylogenetic approaches.

The phylogenetic trees of SLC-like protein families presented in S1 File can be instrumental for functional

annotation based on orthology analysis in lower organisms, as well for studying species-specific differences

in transport pathways. Of particular note, different orthologs of hepatic drug transporters are present in

humans and experimental mammals used in pre-clinical studies, contributing to imperfect prediction of drug

half-life and toxicity in animal models [41]. On the other hand, genetic ablation of transporters and

phenotype studies in lower organisms could shed light on the function of their human orthologs. However,

as can be seen in Fig 2 and the phylogenetic trees in S1 File, a significant number of SLC-like protein

sequences were found in *D. melanogaster* and *C. elegans* that do not appear to have orthologs in the higher

organisms studied here. Most of these protein sequences are poorly annotated and their expression and

function have yet to be confirmed.

The interesting cases of apparent outlier sequences in several families (SLC5A7, SLC10A7, SLC25A46,

SLC30A9, SLC39A9, MPDU1/SLC66A5 as well as the SLC9B and SLC35 families) have previously been partially

documented. These members show striking sequence and/or functional divergence from other members of

their SLC families. SLC5A7 diverges from other SLC5 proteins in phylogenetic trees [42,43] and shares only

20-25% sequence identity with them [44]. The sequence of SLC10A7 is more similar to its bacterial relatives

than to other SLC10 members, and its genetic structure, particularly its number of exons, is also different

from other proteins in the SLC10 family [45,46]. SLC10A7 also appears to have diverged at the functional

level, as it has been suggested to be a regulator of Ca^{2+} influx [47], while having no documented transport

activity. SLC25A46 turns out to be an outer mitochondrial membrane protein [48], in contrast to most other

members of the SLC25 family, which are generally located on the inner mitochondrial membrane. Consistent

with this, its yeast ortholog Ugo1, referred to as "a degenerate member of the mitochondrial metabolite

carrier family", was reported to be part of the mitochondrial outer membrane fusion machinery [49].

Similarly, MTCH1 and MTCH2, which also seem to be distantly related to other SLC25 members according to

our dendrogram (Fig 1), are also outer mitochondrial membrane proteins [50,51], and together with

SLC25A46, are collectively referred to as "peculiar" members of the family [52]. SLC30A9 is found in the

cytosol and nuclear fractions and functions as a coactivator of nuclear receptors after hormonal stimulation

[53], in contrast to other members of the family, which are Zn^{2+} transporters. SLC39A9, the only member of

"subfamily I" of Zrt/Irt-like proteins (ZIPs) [37] might function as an androgen hormone receptor [54], while

most other family members are primarily transporters of divalent metal ions. SLC9B subfamily proteins

NHA1 and NHA2 of the SLC9 Na^+/H^+ exchanger family are more similar to their bacterial homologs than to

SLC9A members [55].

In the following sections, we discuss the non-classic set of human SLC-like proteins resulting from our search,

with a particular focus on the identities of the transported substrates and, if known, the structural and

mechanistic aspects of transport. In certain cases, the proteins have already been officially included in the

SLC nomenclature as per our initiative and as a result of the precursor of this work, following approval by the

Human Gene Nomenclature Committee (HGNC). Where existing information about substrate and function is

not available, we have speculated on these aspects using available information in the literature and

considerations of sequence similarity. For several proteins, however, their classification requires further

consideration. We would also like to articulate open questions about what further work is needed in order to

identify additional transporters. We believe our approach has been useful to pinpoint proteins that have a

high probability of being novel transporters. Thus, specific biological, biochemical and structural efforts

could focus on these specific targets highlighted in our work, all of which would contribute to a complete

assessment of the SLC-ome in human cells.

507 Transporters with existing evidence for transport function

Importantly, our search highlighted several proteins for which our literature search uncovered previously

reported evidence of transporter activity. Several of the proteins in these families have been assigned SLC

family numbers and, in collaboration with the HGNC, included in the SLC nomenclature. Among these hits

are several mitochondrial transporters (MPC/SLC54, LETM/SLC55, Sideroflexins/SLC56), which have been

reviewed before [56]. In terms of transported substrate, many of the proteins with documented transport

activity appear to be ion transporters or exchangers (Table 3). In the next paragraph, we will highlight certain

proteins and families that have particularly caught our attention.

Interestingly, the **SLC60** family contains two MFS-like proteins (MFSD4A, MFSD4B), of which MFSD4B has

been shown to transport D-glucose and urea [57,58].

The **SLC61A1** protein (MFSD5) is the only protein in human that shows similarity to the #2.A.1.40 family of

molybdate transporters and contains the "MFS_5" Pfam model. It has been claimed to be the homolog of

similar transporters from algae and plants, and complementation assays suggested its ability to transport

molybdate [59]. While molybdenum is a biologically active trace element, not much is known about its

transport and homeostasis in human [60].

Interestingly, the **TMEM163** protein clustered together with SLC30 zinc transporter (ZnT) proteins, since the

"Cation_efflux" Pfam model, representative of the SLC30 family, was present in its sequence, although at a

low score and non-significant e-value (2.9e-3). In the TCDB, TMEM163 is also classified under subfamily

#2.A.4.8, sharing a common family with SLC30 transporters (#2.A.4.2). Multiple sequence alignment as well

as pairwise alignments with existing SLC30 members reveal very low sequence identity with SLC30 proteins

(4.2-14.4%), albeit these numbers are similar to those of SLC30A9 (6.5-13.4%). Given the marginal similarity

to the "Cation_efflux" domain, it is tempting to assume that SLC30 proteins and TMEM163 are distantly

related. Indeed, TMEM163 has been shown to bind [61] and transport Zn^{2+} [62–64], and substitution of its

proposed substrate-binding residues with alanine abolished Zn^{2+} efflux activity [64]. Transport has been

demonstrated to be H^+-coupled, and the protein functioning as a dimer [62], while extruding Zn^{2+} from the

cell [64]. Intracellularly, TMEM163 was originally shown to be expressed in synaptic vesicles [65]. In

overexpression systems, it is localized to both the plasma membrane and intracellular membrane

compartments [64]. TMEM163 has been linked to Parkinson's disease (PD) [66], even though the opposite

conclusion has also been drawn [67]. TMEM163 has also been reported to be upregulated by olanzapine, a

psychotropic drug prescribed for PD patients [68]. In addition, TMEM163 was also shown to be highly

expressed in insulin secretory vesicles in human pancreas [69], and has been identified as a risk factor in type

2 diabetes [70,71]. Disruption of TMEM163 expression might impair insulin secretion at high glucose stimuli

[69].

The **TMEM165** protein clustered into its own family and is the only protein in human containing the

"UPF0016" Pfam domain and showing similarity to TCDB family #2.A.106.2. TMEM165 is a member of a

highly conserved family of transmembrane proteins that is present in many species of eukaryotes and

bacteria [72]. Initially, TMEM165 and its yeast homolog, Gdt1p, have been hypothesized to be Ca^{2+}/H^+

exchangers [73,74]. However, recently, evidence has been mounting about its involvement in manganese

(Mn^{2+}) homeostasis [74], and both Ca^{2+} and Mn^{2+} transport activity has directly been shown [75]. TMEM165

is localized to the trans-Golgi in human cells [72], and is proposed to play a crucial role in regulating Mn^{2+}

uptake into the Golgi apparatus [72,74]. In line with this, its homologs in other organisms, also containing

548 the UPF0016 domain, are also annotated as Mn^{2+} transporters [74]. Manganese plays an important role as a

549 co-factor for enzymes involved in glycosylation, and impairment of TMEM165 function results in

550 glycosylation defects. Indeed, mutations of TMEM165 found in patients with congenital disorder of

551 glycosylation (CDG) type II hamper the transport function or localization of TMEM165 [75]. Due to the

552 importance of TMEM165 in lactate biosynthesis [76], it has also been suggested that TMEM165 could be a

553 transporter importing both Ca^{2+} [77] and Mn^{2+} into the Golgi in exchange for protons [74]. TMEM165

554 proteins contain two copies of the UPF0016 domain, and each domain contains a signature motif, E-φ-G-D-

555 (K/R)-(T/S), where φ denotes a hydrophobic amino acid. The glutamic acid of the second motif, E248, has

556 been shown to be crucial for affecting the glycosylation function of the Golgi but not the expression of the

557 protein [78], and so can be speculated to form part of a binding site for transporter function. However, in

558 the absence of an experimentally determined structure, further investigation will be required to understand

559 the transport mechanism of TMEM165.

Proteins with sequence similarity to existing transporters

561 Our search uncovered a large number of proteins that show sequence similarity and thus possible

562 relationships to existing transporters in the SLC nomenclature. Since transport activity has not been

563 demonstrated, these proteins are either orphan transporters or they could have transceptor functions. What

564 follows is a comprehensive discussion of these proteins, as their similarity to transporters makes them ideal

565 targets for further studies to elucidate their putative transporter activity.

Atypical transporters

567 A previous effort by Perland and coworkers has uncovered novel transporter-like proteins mostly from the

568 MFS and APC superfamilies [11], which have also been recognized by our search. In general, the function of

569 these atypical transporters is not well known, but some have been reported to be expressed in the brain,

570 and their expression levels seem to be affected by nutrient availability [79–82]. For MFSD1, MFSD6 and

571 UNC93A, the study of the *D. melanogaster* and *C. elegans* orthologs have provided some information on the

572 loss-of-function phenotype [83–86]. MFSD8 and MFSD10 have been linked to the Wolf-Hirschhorn syndrome

573 and to LINCL (late-infantile-onset neuronal ceroid lipofuscinoses), respectively [87,88], and MFSD8 seems to

be localized in the lysosomes [89,90]. More studies about the biological function and transport activity of

these proteins is required to fully understand their physiological roles.

Some of the "atypical" SLC-like transporters (e.g. MFSD8, MFSD9, MFSD10 and MFSD14 proteins) clustered

together with members of the classical SLC18 family, which prompted us to examine the relationship of

these and neighboring proteins in more detail. We constructed multiple alignments and a phylogenetic tree

of the proteins one level above these proteins in our clustering dendrogram (i.e., members of the SLC17,

SLC18, SLC37 families as well as MFSD8, MFSD9, MFSD10, MFSD14A-C and SLC22A18 proteins, Fig 3). As

expected, the phylogenetic tree gives a better separation of these very similar proteins than the HMM

fingerprint-based dendrogram, and the branch support values suggest a clear separation of the SLC17, SLC18

and SLC37 families. In addition, the phylogenetic tree highlights that the atypical SLC proteins MFSD8,

MFSD9, MFSD10, MFSD14A-C as well as SLC22A18, while being more divergent, are likely to have evolved

from a single common ancestor. The relationship between the MFSD9, MFSD10 and MFSD14A-B proteins

also agrees with earlier studies [10,11]. Similarly, the evolutionary dendrogram created using all 7 organisms

in our study for the SLC18 family (S1 File) suggests that MFSD9, MFSD10, MFSD14A-B and SLC22A18 likely

share a common evolutionary origin and are thus more closely related to each other than to SLC18 proteins,

while MFSD8 is more distantly related. Further studies may be required to elucidate the particular

evolutionary relationship between these proteins.

Figure 3. Phylogenetic tree of the SLC17, SLC18 and SLC37 families and proteins clustering in their

neighborhood. Branch support values ≥ 0.7 are shown.

Interestingly, **MFSD3** has clustered together with the SLC33A1 protein in our HMM fingerprint-based

clustering analysis. Indeed, the "Acatn" (Acetyl-coenzyme A transporter 1) Pfam domain is present in MFSD3,

albeit with a relatively low score, but with significant e-value (5.6e-12). Sequence alignment between

SLC33A1 and MFSD3 gives 18.2% sequence identity. Even though the sequence identity between MFSD3 and

SLC33A1 is relatively low, the "Acatn" domain was found only in these proteins. The relatedness of MFSD3

and SLC33A1 is also corroborated by previous results of other groups [81]. The biological function of MFSD3

is still unclear [81,91,92].

The **TMEM104** protein in our analysis clustered together with amino acid transporter families SLC32, SLC36

and SLC38. Based on multiple and pairwise sequence alignments and sequence identity, TMEM104 was most

similar to SLC38A7 (13.3-15.1%), SLC38A8 (13.1-15.1%), and SLC36A1 (10.9-16.1%). Interestingly, TMEM104

also bears moderate similarity to the "Aa_trans" Pfam domain, which describes the transmembrane region

of SLC38 proteins. In our SLC classification dendrogram (Fig 1), TMEM104 clustered with SLC38 proteins,

even though it seems to be an outlier from the family, similarly to SLC38A9. In addition, TMEM104, SLC38A7

and SLC38A8 all show low similarity to the "Trp_Tyr_perm" Pfam domain, which describes bacterial tyrosine

and tryptophan permeases. Despite the low sequence similarity to SLC38 members, these data suggest that

TMEM104 might be an amino acid transporter distantly related to the SLC38 family. To get a more detailed

picture of the evolutionary relationship of TMEM104 and the SLC38, SLC36 and SLC32 families, we

constructed a multiple alignment and a phylogenetic tree of these proteins (Fig 4). While the tree

undoubtedly separates the SLC32 and SLC36 clades due to high branch support values, TMEM104 could not

be clearly separated from the SLC38 family, and it likely has a similar relationship to the rest of the family as

SLC38A9, which is playing a transceptor role in cells [93]. However, there is currently no experimental

evidence for this and the biological function of TMEM104 remains elusive.

Figure 4. Phylogenetic tree of proteins clustering in the SLC38-36-32 families and TMEM104. Branch

support values ≥ 0.5 are shown. SLC32 and SLC36 family members are colored gold and blue, respectively.

Proteins similar to SLC35 transporters

Interestingly, our search revealed several proteins that show sequence similarity to transporters of the

SLC35 family. SLC35 proteins are currently classified into subfamilies A-G, which have relatively low

sequence identity among them (4.0-22.0%). SLC35 transporters belong to the family of "DMT" (drug-

metabolite transporters), which is classified in TCDB family #2.A.7, and corresponds to a clan of Pfam

families, called DMT. Currently known substrates of human SLC35 members include nucleotide-sugar

conjugates [40]. However, the substrate range of this superfamily is substantially larger [94].

The **TMEM144** proteins harbors its dedicated Pfam model called "TMEM144", which itself is a member of

the DMT clan of transporters. Its relatedness to the DMT family is further corroborated by high-scoring

similarity of the TCDB subfamily #2.A.7.8 to the sequence of TMEM144. Otherwise, functionally, the protein

is uncharacterized, although it might be related to sterol metabolism/transport, because its function has

been linked to bovine milk cholesterol levels [95], the hypothalamic-gonadal axis and testosterone response

[96]. It is also highly expressed in the hypothalamus [96].

TMEM234 is classified in the TCDB #2.A.7.32 family and also contains a corresponding "TMEM234" Pfam

domain, which is a member of the "DMT" clan of Pfam domains as well. The physiological role of TMEM234

is not known. However, in zebrafish, its homolog might play a role in the formation of the kidney filtration

barrier, as its knockdown causes proteinurea [97].

In our clustering analysis, **TMEM241** clustered with the SLC35 family very closely. Its HMM fingerprint shows

similarity to the TC# 2.A.7.13 subfamily, and weak similarity to the "TPT" Pfam model (which also belongs to

the "DMT" Pfam clan) over the whole length of the protein. The proteins in the #2.A.7.13 family are Golgi

GDP-mannose:GMP antiporters from plants, yeast and other organisms [98,99], but not from vertebrates.

Nevertheless, the protein seems to be present in many higher organisms according to the Swiss-Prot

database. However, these protein are not listed in the TCDB. The biological function of TMEM241 is still

unknown, but it has been suggested to affect serum triglyceride levels [100].

Due to the sequence diversity of the SLC35 family, we were interested in the relationships between

individual proteins. To this end, we have built a phylogenetic tree of human proteins that showed similarity

to existing SLC35 transporters (Fig 5). In the tree, most SLC35 subfamilies could be resolved as a single clade,

while TMEM241 and TMEM234 form clades with SLC35D and SLC35F3-5 proteins with a support value of

0.91 and 0.71, respectively. The relationship of TMEM241 with the SLC35D subfamily is also supported by

our HMM fingerprint-based clustering results. TMEM241 shows 12.0-21.4% sequence identity with SLC35D

proteins. In contrast, our phylogenetic tree with SLC35 proteins from all 7 organisms (S1 File) indicated that

TMEM241 is most closely related to SLC35E4. On the other hand, TMEM234 only weakly associated with

SLC35F proteins, with sequence identities 3.6-9.2%. TMEM144 appears to be only distantly related to SLC35

proteins. The elucidation of evolutionary relationships between proteins in the SLC35 thus likely requires

further investigation.

Figure 5. Phylogenetic tree of proteins with HMM fingerprints overlapping with the SLC35 family. Branch

support values ≥ 0.7 are shown. The different subfamilies are colored in various colors.

658
659

Others

GPR155 is an enigmatic protein that seems to be a concatenation of a membrane transporter domain (Pfam:

"Mem_trans") and a G-protein coupled receptor (GPCR) domain, which might be the reason why it is

annotated as a GPCR. The membrane transporter part seems to be most similar to TCDB #2.A.69.3 subfamily

proteins, which are annotated as malate/malonate transporters in the Auxin Efflux Carrier (AEC) family

(#2.A.69). Gene structure analysis suggests that the concatenation is real [101], and both the human, mouse

and fruitfly proteins seem to contain 17 TMHs according to UniProt annotations.

The "Mem_trans" domain is only present in GPR155 from all human proteins analyzed, and matches the first

10 TMHs of the protein in a 5+5 arrangement. In our structural search, the second half of this transporter

domain (TMHs 6-10) of GPR155 exhibits similarity to the N-terminal half of sodium/bile transporters of the

AsbT fold (SLC10 family). On the other hand, the last 7 TMHs of GPR155 (TMHs 11-17) indeed show

similarity to GPCR-fold (7-TM) proteins with known structure, with highest similarity to structures of the

human Smoothened receptor homolog (PDB ID: 6OT0). Interestingly, in our search, the N-terminal half of the

transporter domain of GPR155 did not show any structural homologues.

The precise function of GPR155 still remains elusive. However, because highest expression levels were found

in the brain, especially in GABAergic neurons, it might play a role in GABAergic neurotransmission [101]. It

also has been suggested that GPR155 might play a role in neurons involved in motor brain function as well as

sensory information processing [101]. In *D. melanogaster*, knockdown of the homologous gene, "anchor",

resulted in increased wing size and thickened veins [102]. This phenotype was similar to what appeared in

bone morphogenetic protein (BMP) signaling gain-of-function experiments [102]. GPR155 has also been

linked to a number of different cancers [103,104].

The **RFT1** protein was originally thought to be a scramblase of lipid-linked origosaccharides [105]. However,

these molecules have at least 12-14 sugar moieties, so given their size, it is unlikely that a single transporter

could catalyze their flipping. Later studies refuted the scramblase concept and suggested instead that RFT1

could serve as an accessory protein to a flippase, but would not act as a flippase itself [106–108].

Nevertheless, the corresponding "Rft1" Pfam model shows similarity to multidrug and toxic compound

extrusion (MATE) transporters (SLC47 family) and belongs to a clan of Pfam domains ("MviN_MATE") that

contains transporters as well. In line with this, human RFT1 showed significant similarity to MATE

transporters in our search for structural homologs, indicating likely structural similarity. Some members of

the corresponding TC# 2.A.66.3 subfamily also contain weak hits of the "MatE" Pfam domain. Thus, while

RFT1 shows similarity to existing transporters, its biological function is still unclear.

The C-terminal half of the **TMEM245** protein shows weak similarity to TC# 2.A.86 proteins (Autoinducer-2

Exporter/AI-2E family), which contain both small-molecule exporters [109,110] as well as Na^+/H^+ antiporter

proteins [111–113]. Accordingly, TMEM245 also has weak similarity to the corresponding Pfam model ("AI-

2E_transport").

The HMMs of TC# 2.A.86 and #2.A.86.1 match residues 444-866 of human TMEM245, which are the last 6

TMHs according to UniProt predictions. The last 5 TMHs are separated from the previous ones by a slightly

larger loop. This architecture is similar to the 3+5 arrangement of the previously described bacterial

$Na^+(Li^+)/H^+$ antiporter TC# 2.A.86.1.14 according to UniProt predictions (accession code: NLHAP_HALAA). This

bacterial protein also matched the full-length "AI-2E_transport" domain from Pfam, while only the last 5

TMHs of TMEM245 match with C-terminal region of "AI-2E_transport". The human TMEM245 protein

contains 14 TMHs in total according to UniProt predictions. Thus, TMEM245 might have a transporter-like

domain at the C-terminus. In terms of the structure, we have not found any similarities to proteins with

known structure. Therefore both TMEM245 and bacterial exporters and antiporters in the TC# 2.A.86 family

are likely to have a yet uncharacterized tertiary structure. Functionally, the TMEM245 protein also remains

elusive.

The **TMEM41A**, **TMEM41B**, and **TMEM64** proteins clustered to the same family in our results. These are the

only proteins in human that show any similarity to the "SNARE_assoc" Pfam domain, as well as to the TCDB

family #9.B.27. While no protein with this domain or from this family has direct evidence for transport

activity, Pfam reports SCOOP-based similarity [31] of the "SNARE_assoc" domain with "Sm_multidrug_ex",

which is a domain encoding transporter proteins. Some members of the family in the TCDB have been

proposed to be "cation:proton importers" (#9.B.27.2.2) or "selenite transport proteins" (#9.B.27.2.3).

The most characterized member of the human protein family is TMEM41B. Interestingly, a recent study

reported a putative structure generated *ab initio* using evolutionary covariance-derived information [114].

Strikingly, this structural model shows features reminiscent of secondary transporters, such as a tandem

internal repeat with two-fold rotational symmetry, and the authors suggest a H^+ antiporter activity as a

mechanism of transport [114].

While the exact function of TMEM41B is still unclear, it forms a complex with vacuole membrane protein 1

(VMP1), also harboring the "SNARE_assoc" domain, and both are required for autophagosome formation

[115,116]. Tmem41b localized to mitochondria-associated ER membranes [117–119]. Interestingly,

TMEM41B seems to be an absolutely required factor for SARS-CoV-2 [120], and probably also flaviviral [121]

infection, possibly by facilitating a membrane curvature that is beneficial for viral replication [121].

The proteins **TMEM184A**, **TMEM184B**, **TMEM184C** clustered together with **SLC51A** (family of transporters of

steroid-derived molecules) in our analysis. While human TMEM184B and SLC51A are included in the TCDB as

members of family #2.A.82, TMEM184A and C are not. Independently, the "Solute_trans_a" Pfam model was

found in all four proteins with high scores and significance, but not in other human proteins. Therefore, it is

likely that the four proteins, TMEM184A-C and SLC51A, are homologous. In spite of this, sequence identity

between TMEM184 proteins and SLC51A is low (12.3%-13.6%), but moderate among TMEM184 proteins

(26.5%-62.0%). All four proteins are predicted to harbor 7 TM helices according to UniProt, yet our search

has found no similar proteins with known structures.

TMEM184A was identified as a heparin receptor in vascular cells [122], but no transport activity has been

reported. Interestingly, while SLC51A is known to function as a bile acid transporter [123–125], TMEM184B

has been proposed to be responsible for ibuprofen uptake [126]. This is interesting in view of the partial

chemical similarity between steroid acids and ibuprofen, both harboring a hydrophobic hydrocarbon part

and a carboxyl moiety. TMEM184C resides in a genetic locus that has been suggested to be responsible for

the pathogenicity of X-linked congenital hypertrichosis syndrome [127], but no transport activity has been

suggested.

Putative transporters

Our search also identified proteins whose transport activity is either controversial or not characterized, and which do not show sequence similarity to transporters of known function. Thus, the proteins in these families require further investigation to uncover their function.

The **CNNM1-4** proteins (also called ACDP1-4) are distant homologs of the cyclins, but have no documented enzymatic activity. Instead, CNNM proteins belong to a highly conserved family of Mg^{2+} transport-related proteins [128], and CNNM2 and CNNM4 have been proposed to be the long sought after basolateral Na^+/Mg^{2+} exchangers in the kidney and intestine, respectively [129,130]. The function of these proteins is, however, controversial [131–134], and there are hypotheses that CNNM proteins *per se* are not Mg^{2+} transporters [135]. Most recently, however, the structure of a bacterial homolog, CorC, has been resolved, revealing its membrane topology, as well as a conserved Mg^{2+}-binding site [136]. Strikingly, the Mg^{2+} ions in the structure are fully dehydrated, in contrast to those in other known Mg^{2+} channel structures [136], which makes it unlikely that the proteins function via a channel-like transport mechanism. In line with this, the authors suggest an alternating-access exchange mechanism [136], however, further studies are required to understand how and whether CNNM proteins might be able to mediate the translocation of Mg^{2+} ions across the membrane.

A family of 4 lysosomal-associated transmembrane proteins (**LAPTM4A**, **LAPTM4B**, **LAPTM5** and sequence **B4E0C1**) turned up in our search, corresponding to the TCDB subfamily #2.A.74.1 and Pfam model "Mtp" (mouse transporter protein). The family also includes an uncharacterized transcript with the UniProt accession "B4E0C1". Originally, the mouse transporter protein (Mtp, ortholog of LAPTM4A) was characterized as a transporter mediating the transport of nucleosides and nucleobases between the cytoplasm and intracellular compartments [137], and was later also associated with multidrug-resistance (MDR) in yeast, where its expression changed the subcellular compartmentalization of a heterogenous group of compounds [138,139]. LAPTM4A was shown to be involved in glycosylation and glycolipid regulation [140,141]. All three proteins seem to be lysosomal [137,142,143]. Nevertheless, these proteins appear to interact with other characterized transporters, such as SLC22A2 (hOCT2), SLC7A5/SLC3A2 (LAT1/4F2hc) and

MDR-related ABC transporters [144–146]. But it has been claimed that they are not *per se* transporters, but

rather regulatory factors, either assisting the localization and targeting or the function of other transporters

[146]. Interestingly, the transcript "B4E0C1" appears to have 4 TMHs at its N-terminus, which is identical to

human LAPTM5 apart from a ~40-amino acid insertion between TMH3 and TMH4. This region also shows

significant similarity to both the "Mtp" Pfam model and the TC# 2.A.74.1 subfamily. However, the C-terminal

region of the transcript is identical to the C-terminal segment of "actin filament-associated protein 1-like 1"

protein (UniProt accession Q8TED9). We did not find any similar fusion sequences in the other organisms we

analyzed. The "Mtp" Pfam domain, which is the hallmark of the family, belongs to the "Tetraspannin" Pfam

clan, which has no other domains with annotated transporter function and no similarity to existing

transporters. Structural information on "Tetraspannin" proteins is also not available. In summary, the

transport function of these proteins requires further investigation.

Our search identified four proteins in human (**LMBR1**, **LMBR1L**, **LMBD1/LMBRD1**, **LMBRD2**) bearing the

"LMBR1" Pfam domain, which clustered into two families in our analysis. These proteins correspond to TCDB

family #9.A.54. The LMBD1 protein, encoded by the LMBRD1 gene, was suggested to function as a vitamin

B12 (cobalamin) transporter, exporting vitamin B12 from the lysosomes into the cytoplasm [147]. However,

it was later shown that LMBD1 actually interacts with ABCD4 and assists in its lysosomal trafficking [148],

and that ABCD4 transports vitamin B12 even in the absence of LMBD1 [149]. Therefore, it is likely that

LMBD1 itself is not a vitamin B12 transporter. LMBD1 was originally coined as having "significant homology"

to lipocalin membrane receptors [147], and indeed the LIMR (lipocalin-1-interacting membrane receptor)

protein, encoded by the LMBR1L gene, is responsible for binding lipocalin 1 (LCN-1) with high affinity

[150,151]. LMBRD2 was proposed to be a regulator of β2-adrenoceptor signaling [152], while the first

protein identified in the family, LMBR1, was associated with polydactyly and limb malformations [153,154].

However, its physiological role is still elusive. The proteins seem to contain 9 TMHs in a 5+4 arrangement

according to UniProt predictions, but the tertiary structure of the proteins is still unknown, and no homologs

with a known structure were found in our search.

Two MagT1-like proteins (**MAGT1** and **TUSC3**), as well as **OSTC** and **OSTCL** (oligosaccharyltransferase

complex subunit) turned up in our search, showing similarity to TCDB family #1.A.76 members. MAGT1 and

TUSC3 also have high-scoring hits for the Pfam domain "OST3_OST6", which is characteristic of members of

the oligosaccharyltransferase (OST) complex. TUSC3 (also called N33) was first identified as a tumor

suppressor gene [155], and its presence, together with that of MAGT1 in the OST complex has been attested

later on [156–160]. Therefore, it was suggested that these proteins act as oxidoreductases [159]. Meanwhile,

MAGT1 and TUSC3 were also proposed to act as Mg^{2+} transporters [161,162]. On the other hand, recent

structural findings of human MAGT1 [160] indicated that this protein may not function as a transporter or

channel due to the lack of substrate-binding site or pore. OSTC (also called DC2) has similarly been shown to

be part of the OST complex and to have a structure similar to MAGT1 [160]. Whether MagT1-like proteins

still have a transport function remains to be clarified.

The **TMEM14A**, **TMEM14B** and **TMEM14C** proteins are the only ones in human containing the "Tmemb_14"

Pfam domain. While Pfam lists this domain as functionally uncharacterized, a plant protein (FAX1) containing

this domain was suggested to be involved in fatty acid export from chloroplasts [163]. However, the

physiological roles of TMEM14A and TMEM14B in human remain elusive. The third member of the family,

TMEM14C, was identified as a putative mitochondrial protein whose transcript is consistently coexpressed

with proteins from the core machinery of heme biosynthesis [164]. It was later shown that TMEM14C

mediates the import of protoporphyrinogen IX (PPgenIX) into the mitochondrial matrix [165,166]. While the

structure of TMEM14C was solved using nuclear magnetic resonance (NMR) [167], showing a bundle of three

TM helices and an amphipathic helix, the transport mechanism remains elusive. Interestingly, despite their

proposed function in the mitochondria, TargetP-2.0 [168] did not predict a mitochondrial targeting sequence

in the amino acid sequence of any of the human TMEM14 proteins in our hands.

TMEM205 is a 4-TMH protein according to UniProt annotations, which was linked to cisplatin resistance

[169]. The protein is expressed mostly in liver, pancreas and adrenal glands, and is present on the plasma

membrane [169]. TMEM205-mediated resistance was shown to be selective towards platinum-based drugs,

such as cisplatin and oxaliplatin, but not carboplatin [170]. While structural information about the protein is

not available, mutagenesis studies of TMEM205 showed that mutating sulfur-containing residues, especially

in TMH2 and TMH4, diminishes the effect of cisplatin resistance [170]. Nevertheless, neither the biological

function nor the physiological substrates of TMEM205 are known.

817 Transporters with hydrophobic substrates

In addition to proteins that transport solutes or are similar to transporters that typically translocate water-

soluble small molecule compounds, our search has uncovered numerous proteins that have been reported

to take part in modulating the intracellular distribution of hydrophobic or amphipathic compounds, such as

cholesterol, fat-soluble vitamins, lipids and fatty acids (Table 3). Although these proteins do not, strictly

speaking, transport so-called "solutes", they translocate small hydrophobic molecules that have

fundamental biological functions. Thus one could argue that they belong to the SLC superfamily as well.

Accordingly, they have been integrated in our search and some of them have already been included in the

SLC nomenclature (SLC59, SLC63, SLC65). In view of the biological and pharmaceutical importance of the

transport mechanisms of hydrophobic substrates, our results on this topic will be discussed in a separate

paper.

828 Conclusions

Our study represents the first systematic correlation of the SLC and TCDB nomenclature schemes. Many of

the transport proteins discovered in our search are underexplored and there is limited information about

them, although they often have important physiological roles and/or potentially represent new therapeutic

targets. Even with proteins that have been studied for their physiological involvement, it was often not taken

into account that they could have a transport function. Numerous proteins uncovered in our search have

similarity to proteins with transport function in other organisms, but their physiological substrates remain

unknown. These proteins will be interesting targets for deorphanization studies in order to reveal their

natural substrates. In our work, we also highlight proteins for which transport activity has been

controversial, and more specific analyses are required to clarify their biological function. In addition, our

search reveals new SLC-like proteins that have no structural information. This hinders a deeper

understanding of their transport mechanism. Future structure determinations would be of crucial

importance to accelerate validation of the identified proteins. The combination of all these efforts would

greatly facilitate the completion of the SLC-ome in human cells. Thus, our study points out important

directions in which future studies could help resolve the lack of information about SLC transporters, which

will help unlock their therapeutic potential.

Acknowledgements

We acknowledge support by the Swiss National Science Foundation for the grants # CRSII5_180326 ("The

role of mitochondrial carriers in metabolic tuning and reprogramming by calcium flow across membrane

contact sites") and # 310030_182272 ("Intestinal absorption of transition metals in human health and

disease") as well as by the Swiss National Research Programme NRP 78, # 4078P0_198281 ("New insights

into the COVID-19 pandemic"). Calculations were performed on UBELIX (http://www.id.unibe.ch/hpc), the

HPC cluster at the University of Bern.

Methods

HMM building for TCDB families and subfamilies

Sequences of selected TCDB families and subfamilies were aligned using PSI-Coffee 11.00 [171] and NCBI

BLAST+ 2.6.0 [172] using the "nr" BLAST database of 2018-02-12. PSI-Coffee was run with BLAST mode

"LOCAL" and otherwise with default options. Altogether, 4221 different sequences from the TCDB were

present in the subfamily and family alignments, and the profiles used for alignments contained 1-1070

sequences. In total, 130 sequences from the TCDB returned zero hits from the "nr" database in the iterative

BLAST searches, meaning their profiles just contained the query sequence itself. PSI-Coffee uses the profiles

to guide the generation of multiple alignments of the query sequences within each subfamily and family. The

alignments were subsequently turned into HMMs using the "hmmbuild" command of HMMER 3.1b2 [30]

using default settings.

Sequence similarity search

All protein belonging to each of the 7 organisms studied were downloaded from UniProt on 2019-07-31 into a FASTA file. Sequence similarity search was performed using the HMMs downloaded for selected Pfam families on 2019-02-14 and those generated for selected TCDB families and subfamilies using "hmmsearch" from HMMER 3.1b2. Hits with bit scores larger than 50 were used for further analysis. These hits presented a maximal hit e-value of 7.9e-12, while hits with bit score larger than 25, used for HMM fingerprint-based clustering (see below), had hit e-values below 6e-4.

Sequence clustering for fragment elimination

Since the downloaded protein set from UniProt contained fragments as well as predicted open reading frames and sequences from genomic screening methods, we strived to retain one sequence per gene for further analysis. In order to achieve this, hits yielded by the sequence similarity search were clustered using the following method. First, all-against-all similarity searches were performed using NCBI BLAST+ 2.4.0 [172]. Sequences were assigned the same cluster if they either share common gene annotations according to their UniProt records, or a high-scoring segment pair (HSP) with more than 95% sequence identity based on the all-against-all BLAST search. For gene annotation, the fields Gene Symbol (GN), HGNC symbol, GeneID, UniGene, FlyBase, KEGG identifiers were used from UniProt records. Ambiguous or conflicting annotations, as well as annotations conflicting with BLAST-reported sequence similarity were detected and resolved manually. Afterwards, clusters were reduced to representative sequences. For clusters containing a single Swiss-Prot sequence, that sequence was taken as representative. For cluster with no Swiss-Prot sequence, the longest sequence of the cluster was taken as representative. Clusters with more than one Swiss-Prot sequence were manually analyzed and split if necessary.

HMM fingerprint-based sequence clustering

We introduce the concept of a "HMM fingerprint", which is a mathematical vector of numbers assigned to a protein sequence, corresponding to the bit scores of similarity to each of the set of HMMs used in our analysis, consisting of the HMMs of TCDB families and subfamilies, as well as Pfam HMMs. We have restricted the number of HMMs to those that gave a hit with bit score > 25, in total 513 HMMs. Two proteins

sequences that are related are expected to show similarity to a similar subset of TCDB families, subfamilies,

or Pfam families, and therefore a similar pattern in their HMM fingerprints. In turn, if two protein sequences

show similarity to the same subset of TCDB families, subfamilies or Pfam families, as indicated by a similar

HMM fingerprint, then they can be expected to be related. Once the HMM fingerprint has been assigned to

each protein sequence found in our search, the unweighted pair group method with arithmetic mean

(UPGMA) method [173] was used using the cosine metric to arrive at a hierarchical clustering of the

sequences. The tree representing the clustering was cut at 0.7 cosine distance to arrive at branches that

formed the basis of protein families. Join and split constraints have been introduced to keep certain proteins

artificially grouped or separated. If a join constraint was acting between a pair of proteins and they were not

grouped into the same cluster by the default tree cut threshold, then the clustering tree was cut just above

the branch that leads to the smallest cluster containing both proteins. Similarly, split constraints between

two proteins caused the clustering tree to be cut just below the branch containing both proteins, unless the

two proteins were already in different clusters. Join constraints were introduced between the following

protein pairs: SLC5A1-SLC5A7, SLC9A1-SLC9B1, SLC10A1-SLC10A7, SLC25A1-SLC25A46, SLC30A1-SLC30A9,

SLC35C1-SLC35G1, SLC39A1-SLC39A9, and SLC66A1-SLC66A5. Split constraints were introduced between the

following protein pairs: SLC2A1-SLC22A1, SLC17A1-SLC18A1, SLC17A1-SLC37A1, SLC32A1-SLC36A1, and

SLC32A1-SLC38A1. The clustering tree with the resulting families was shown in Fig 1 in a polar coordinate

system, with the radial component ($d \in [0; 1]$) transformed according to $d' = 0.5 + \frac{\arcsin(2d-1)}{\pi}$ to magnify

tree details around $d = 0$ and $d = 1$ for better visual representation.

Structural homolog search

Sequences of SLC-like proteins were turned into HMMs using "hhblits" from the HH-suite3 package [174],

using the UniRef30 database of 2020-06 [35,175], 3 iterations, an E-value threshold of 1e-3 for inclusion, and

a probability threshold of 0.35 for MAC re-alignment. The HMMs were searched against the "pdb70"

database of 2021-08-04 [35] with no MAC realignment, "predicted vs predicted" secondary structure

scoring, and amino acid score of 1. The resulting hits were checked against PDB annotations of

transmembrane helices, and were accepted if at least 3 TM segments were contained within the aligned

region and the E-value of the hit was less than 1e-4.

Phylogenetic trees

Selected groups of SLC-like proteins were aligned using Clustal Omega 1.2.1 [176,177] with 5 iterations and

default settings. Smart Model Selection 1.8.4 [178] and PhyML 3.3.20190909 [179] were used to generate

the phylogenetic trees, with 10 random starting trees and using the approximate likelihood ratio test aLRT

method [180]. Trees in main figures were visualized using TreeViewer 1.2.2 (https://treeviewer.org/). Tree

rooting, rearrangement (with threshold 0.9) and reconciliation with the species tree was done using

NOTUNG 2.9.1.5 [181]. Reconciled phylogenetic trees were visualized using custom Python scripts in the

style used by NOTUNG. Orthologs were identified using the reconciled phylogenetic trees and custom

Python scripts.

Data Availability

925   Scripts and data generated during the preparation of the manuscript are available at

926   https://github.com/bioparadigms/SLCAtlas. In addition, the datasets resulting from this work will also be

927   made available in a browsable format at https://www.bioparadigms.org/.

Supplementary information

S1 Table. "SLC-like" Pfam models and their clan memberships. The dataset is a result of our manual

curation based on our "SLC-like" criteria (see text) and Pfam families present in protein sequences listed in

the TCDB. Family names and data are from the Pfam database.

S2 Table. False positive hits or incorrectly annotated human sequences found in our search. Gene symbol

and protein name shown based on UniProt data. Most similar (highest scoring) TCDB families/subfamilies

and Pfam families are shown, and reason for being false positive are indicated.

S3 Table. Table of existing (classic) SLC transporters, indicating the correlation with TCDB

families/subfamilies, Pfam families, PDB structures and structural folds. Gene symbol and protein name

based on UniProt information are shown. Most similar (highest-scoring) TCDB families and subfamilies, as

well as Pfam families are shown for each protein. The PDB structure from the pdb70 dataset that is most

similar (highest-scoring) to each protein is shown, along with its fold family assignment by us, partly based

on TCDB family names.

AbgT: p-Aminobenzoyl-glutamate Transporter family; Amt: Ammonium Transporter family; APC: Amino acid-

Polyamine-Cation family; CDF: Cation Diffusion Facilitator family; CNT: Concentrative Nucleoside Transporter

family; Ctr: Copper Transporter family; DAACS: Dicarboxylate/Amino Acid:Cation (Na$^+$ or H$^+$) Symporter

family; MATE: Multidrug And Toxic compound Extrusion family; MCF: Mitochondrial Carrier Family; MFS:

Major Facilitator Superfamily; MgtE: Mg^{2+} transporter-E family; NAT: Nucleobase/Ascorbate Transporter or

Nucleobase:Cation Symporter-2 (NCS2) family; NCX: Sodium/Calcium exchanger family; NhaA:

Sodium/proton antiporter family; NST: Nucleoside-Sugar Transporter family; PiT: Type III Sodium/phosphate

cotransporter family; SWEET: Sugar Will Eventually be Transported family.; ZIP: Zrt/Irt-like Transporter

family.

S4 Table. Non-classic "SLC-like" proteins of Table 3 found in our search, extended with additional

information. Protein sequence identifiers, most similar (highest-scoring) PDB structure from the pdb70

dataset, chemical identifiers, PubMed links to references, and comments have been included. The table also

contains information about whether individual SLC-likeness criteria (numbered 1-8) have been satisfied or

violated.

S1 File. Phylogenetic trees of SLC-like protein families with more than two members. Trees were generated

using multiple alignment by ClustalO, maximum likelihood tree generation by PhyML, followed by tree

reconciliation with the species tree using NOTUNG (see Methods). The species tree with internal names of

putative ancestor taxa is shown on each page on the upper-right hand corner. The trees are shown as

dendrograms and branch lengths are not indicative of evolutionary distance. Each tree leaf corresponds to

an SLC-like protein sequence denoting a gene, labels show the gene symbol, UniProt accession and taxon

name. Leaves with labels ending with "*LOST" denote putative genes lost in the indicated ancestral species.

Red "D" denote gene duplication nodes, normal nodes correspond to speciation nodes. Light green numbers

denote branch support values as calculated by NOTUNG.

References

1.   Hediger MA, Romero MF, Peng J-B, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch. 2004;447: 465–468. doi:10.1007/s00424-003-1192-y

2.   Hediger MA, Clémençon B, Burrier RE, Bruford EA. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med. 2013;34: 95–107. doi:10.1016/j.mam.2012.12.009

3.   César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, et al. A Call for Systematic Research on Solute Carriers. Cell. 2015;162: 478–487. doi:10.1016/j.cell.2015.07.022

4.   Bai X, Moraes TF, Reithmeier RAF. Structural biology of solute carrier (SLC) membrane transport proteins. Mol Membr Biol. 2018; 1–32. doi:10.1080/09687688.2018.1448123

5.   Choi S, Jeon J, Yang J-S, Kim S. Common occurrence of internal repeat symmetry in membrane proteins. Proteins. 2008;71: 68–80. doi:10.1002/prot.21656

6.   Forrest LR. Structural Symmetry in Membrane Proteins. Annu Rev Biophys. 2015;44: 311–337. doi:10.1146/annurev-biophys-051013-023008

7.   Jardetzky O. Simple allosteric model for membrane pumps. Nature. 1966;211: 969–970. doi:10.1038/211969a0

8.   Forrest LR, Krämer R, Ziegler C. The structural basis of secondary active transport mechanisms. Biochim Biophys Acta. 2011;1807: 167–188. doi:10.1016/j.bbabio.2010.10.014

9.   Fredriksson R, Nordström KJV, Stephansson O, Hägglund MGA, Schiöth HB. The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families. FEBS Lett. 2008;582: 3811–3816. doi:10.1016/j.febslet.2008.10.016

10.   Perland E, Fredriksson R. Classification Systems of Secondary Active Transporters. Trends Pharmacol Sci. 2017;38: 305–315. doi:10.1016/j.tips.2016.11.008

11.   Perland E, Bagchi S, Klaesson A, Fredriksson R. Characteristics of 29 novel atypical solute carriers of major facilitator superfamily type: evolutionary conservation, predicted structure and neuronal co-expression. Open Biol. 2017;7. doi:10.1098/rsob.170142

12.   Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, Kelly L, et al. Comparison of human solute carriers. Protein Science. 2010;19: 412–428. doi:10.1002/pro.320

13.   Schlessinger A, Yee SW, Sali A, Giacomini KM. SLC classification: an update. Clin Pharmacol Ther. 2013;94: 19–23. doi:10.1038/clpt.2013.73

14.   Saier MH. Molecular phylogeny as a basis for the classification of transport proteins from bacteria, archaea and eukarya. Adv Microb Physiol. 1998;40: 81–136.

15.   Saier MH, Reddy VS, Moreno-Hagelsieb G, Hendargo KJ, Zhang Y, Iddamsetty V, et al. The Transporter Classification Database (TCDB): 2021 update. Nucleic Acids Res. 2021;49: D461–D467. doi:10.1093/nar/gkaa1004

16.   Cao Y, Jin X, Huang H, Derebe MG, Levin EJ, Kabaleeswaran V, et al. Crystal structure of a potassium ion transporter, TrkH. Nature. 2011;471: 336–340. doi:10.1038/nature09731

17.   Bosson R, Jaquenoud M, Conzelmann A. GUP1 of Saccharomyces cerevisiae encodes an O-acyltransferase involved in remodeling of the GPI anchor. Mol Biol Cell. 2006;17: 2636–2645. doi:10.1091/mbc.e06-02-0104

18.   Berks BC, Sargent F, Palmer T. The Tat protein export pathway. Mol Microbiol. 2000;35: 260–274. doi:10.1046/j.1365-2958.2000.01719.x

19.   Berks BC, Sargent F, De Leeuw E, Hinsley AP, Stanley NR, Jack RL, et al. A novel protein transport system involved in the biogenesis of bacterial electron transfer chains. Biochim Biophys Acta. 2000;1459: 325–330. doi:10.1016/s0005-2728(00)00168-7

20.   Ren Q, Kang KH, Paulsen IT. TransportDB: a relational database of cellular membrane
transport systems. Nucleic Acids Res. 2004;32: D284-288. doi:10.1093/nar/gkh016
21.   Ren Q, Chen K, Paulsen IT. TransportDB: a comprehensive database resource for cytoplasmic
membrane transport systems and outer membrane channels. Nucleic Acids Res. 2007;35: D274-
279. doi:10.1093/nar/gkl925
22.   Elbourne LDH, Tetu SG, Hassan KA, Paulsen IT. TransportDB 2.0: a database for exploring
membrane transporters in sequenced genomes from all domains of life. Nucleic Acids Res. 2017;45:
D320–D324. doi:10.1093/nar/gkw1068
23.   Tatusov RL, Natale DA, Garkavtsev IV, Tatusova TA, Shankavaram UT, Rao BS, et al. The COG
database: new developments in phylogenetic classification of proteins from complete genomes.
Nucleic Acids Res. 2001;29: 22–28. doi:10.1093/nar/29.1.22
24.   Haft DH, Selengut JD, Richter RA, Harkins D, Basu MK, Beck E. TIGRFAMs and Genome
Properties in 2013. Nucleic Acids Res. 2013;41: D387-395. doi:10.1093/nar/gks1234
25.   Finn RD, Coggill P, Eberhardt RY, Eddy SR, Mistry J, Mitchell AL, et al. The Pfam protein
families database: towards a more sustainable future. Nucleic Acids Res. 2016;44: D279-285.
doi:10.1093/nar/gkv1344
26.   Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein
topology with a hidden Markov model: application to complete genomes. J Mol Biol. 2001;305:
567–580. doi:10.1006/jmbi.2000.4315
27.   UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res.
2019;47: D506–D515. doi:10.1093/nar/gky1049
28.   El-Gebali S, Mistry J, Bateman A, Eddy SR, Luciani A, Potter SC, et al. The Pfam protein
families database in 2019. Nucleic Acids Res. 2019;47: D427–D432. doi:10.1093/nar/gky995
29.   Finn RD, Mistry J, Schuster-Böckler B, Griffiths-Jones S, Hollich V, Lassmann T, et al. Pfam:
clans, web tools and services. Nucleic Acids Res. 2006;34: D247-251. doi:10.1093/nar/gkj149
30.   Eddy SR. Accelerated Profile HMM Searches. PLoS Comput Biol. 2011;7: e1002195.
doi:10.1371/journal.pcbi.1002195
31.   Bateman A, Finn RD. SCOOP: a simple method for identification of novel protein superfamily
relationships. Bioinformatics. 2007;23: 809–814. doi:10.1093/bioinformatics/btm034
32.   Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A. UniProtKB/Swiss-Prot. Methods
Mol Biol. 2007;406: 89–112. doi:10.1007/978-1-59745-535-0_4
33.   Quednau BD, Nicoll DA, Philipson KD. The sodium/calcium exchanger family-SLC8. Pflugers
Arch. 2004;447: 543–548. doi:10.1007/s00424-003-1065-4
34.   Chen H, Liu Y, Li X. Structure of human Dispatched-1 provides insights into Hedgehog ligand
biogenesis. Life Sci Alliance. 2020;3: e202000776. doi:10.26508/lsa.202000776
35.   Remmert M, Biegert A, Hauser A, Söding J. HHblits: lightning-fast iterative protein sequence
searching by HMM-HMM alignment. Nat Methods. 2011;9: 173–175. doi:10.1038/nmeth.1818
36.   Söding J, Remmert M. Protein sequence comparison and fold recognition: progress and
good-practice benchmarking. Curr Opin Struct Biol. 2011;21: 404–411.
doi:10.1016/j.sbi.2011.03.005
37.   Jeong J, Eide DJ. The SLC39 family of zinc transporters. Mol Aspects Med. 2013;34: 612–619.
doi:10.1016/j.mam.2012.05.011
38.   Donowitz M, Ming Tse C, Fuster D. SLC9/NHE gene family, a plasma membrane and
organellar family of Na^+/H^+ exchangers. Mol Aspects Med. 2013;34: 236–251.
doi:10.1016/j.mam.2012.05.001

39.   Pramod AB, Foster J, Carvelli L, Henry LK. SLC6 transporters: structure, function, regulation,
disease association and therapeutics. Mol Aspects Med. 2013;34: 197–219.
doi:10.1016/j.mam.2012.07.002
40.   Song Z. Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. Mol
Aspects Med. 2013;34: 590–600. doi:10.1016/j.mam.2012.12.004
41.   Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for
translating preclinical findings to humans. Expert Opin Drug Metab Toxicol. 2013;9: 237–252.
doi:10.1517/17425255.2013.741589
42.   Wright EM. Glucose transport families SLC5 and SLC50. Mol Aspects Med. 2013;34: 183–
196. doi:10.1016/j.mam.2012.11.002
43.   Gyimesi G, Pujol-Giménez J, Kanai Y, Hediger MA. Sodium-coupled glucose transport, the
SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application.
Pflugers Arch. 2020;472: 1177–1206. doi:10.1007/s00424-020-02433-x
44.   Haga T. Molecular properties of the high-affinity choline transporter CHT1. J Biochem.
2014;156: 181–194. doi:10.1093/jb/mvu047
45.   Claro da Silva T, Polli JE, Swaan PW. The solute carrier family 10 (SLC10): beyond bile acid
transport. Mol Aspects Med. 2013;34: 252–269. doi:10.1016/j.mam.2012.07.004
46.   Godoy JR, Fernandes C, Döring B, Beuerlein K, Petzinger E, Geyer J. Molecular and
phylogenetic characterization of a novel putative membrane transporter (SLC10A7), conserved in
vertebrates and bacteria. Eur J Cell Biol. 2007;86: 445–460. doi:10.1016/j.ejcb.2007.06.001
47.   Karakus E, Wannowius M, Müller SF, Leiting S, Leidolf R, Noppes S, et al. The orphan solute
carrier SLC10A7 is a novel negative regulator of intracellular calcium signaling. Sci Rep. 2020;10:
7248. doi:10.1038/s41598-020-64006-3
48.   Janer A, Prudent J, Paupe V, Fahiminiya S, Majewski J, Sgarioto N, et al. SLC25A46 is required
for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome.
EMBO Mol Med. 2016;8: 1019–1038. doi:10.15252/emmm.201506159
49.   Sesaki H, Jensen RE. UGO1 encodes an outer membrane protein required for mitochondrial
fusion. J Cell Biol. 2001;152: 1123–1134. doi:10.1083/jcb.152.6.1123
50.   Lamarca V, Sanz-Clemente A, Pérez-Pé R, Martínez-Lorenzo MJ, Halaihel N, Muniesa P, et al.
Two isoforms of PSAP/MTCH1 share two proapoptotic domains and multiple internal signals for
import into the mitochondrial outer membrane. Am J Physiol, Cell Physiol. 2007;293: C1347-1361.
doi:10.1152/ajpcell.00431.2006
51.   Labbé K, Mookerjee S, Le Vasseur M, Gibbs E, Lerner C, Nunnari J. The modified
mitochondrial outer membrane carrier MTCH2 links mitochondrial fusion to lipogenesis. J Cell Biol.
2021;220: e202103122. doi:10.1083/jcb.202103122
52.   Ruprecht JJ, Kunji ERS. The SLC25 Mitochondrial Carrier Family: Structure and Mechanism.
Trends Biochem Sci. 2020;45: 244–258. doi:10.1016/j.tibs.2019.11.001
53.   Chen Y-H, Kim JH, Stallcup MR. GAC63, a GRIP1-dependent nuclear receptor coactivator.
Mol Cell Biol. 2005;25: 5965–5972. doi:10.1128/MCB.25.14.5965-5972.2005
54.   Thomas P, Pang Y, Dong J, Berg AH. Identification and characterization of membrane
androgen receptors in the ZIP9 zinc transporter subfamily: II. Role of human ZIP9 in testosterone-
induced prostate and breast cancer cell apoptosis. Endocrinology. 2014;155: 4250–4265.
doi:10.1210/en.2014-1201
55.   Brett CL, Donowitz M, Rao R. Evolutionary origins of eukaryotic sodium/proton exchangers.
Am J Physiol Cell Physiol. 2005;288: C223-239. doi:10.1152/ajpcell.00360.2004
56.   Gyimesi G, Hediger MA. Sequence Features of Mitochondrial Transporter Protein Families.
Biomolecules. 2020;10. doi:10.3390/biom10121611

57. Horiba N, Masuda S, Takeuchi A, Takeuchi D, Okuda M, Inui K. Cloning and characterization
of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney. J Biol Chem. 2003;278:
14669–14676. doi:10.1074/jbc.M212240200
58. Nawata CM, Dantzler WH, Pannabecker TL. Alternative channels for urea in the inner
medulla of the rat kidney. Am J Physiol Renal Physiol. 2015;309: F916-924.
doi:10.1152/ajprenal.00392.2015
59. Tejada-Jiménez M, Galván A, Fernández E. Algae and humans share a molybdate
transporter. Proc Natl Acad Sci USA. 2011;108: 6420–6425. doi:10.1073/pnas.1100700108
60. Zhu W, Spiga L, Winter S. Transition metals and host-microbe interactions in the inflamed
intestine. Biometals. 2019;32: 369–384. doi:10.1007/s10534-019-00182-8
61. Barth J, Zimmermann H, Volknandt W. SV31 is a Zn2+-binding synaptic vesicle protein. J
Neurochem. 2011;118: 558–570. doi:10.1111/j.1471-4159.2011.07344.x
62. Waberer L, Henrich E, Peetz O, Morgner N, Dötsch V, Bernhard F, et al. The synaptic vesicle
protein SV31 assembles into a dimer and transports Zn2. J Neurochem. 2017;140: 280–293.
doi:10.1111/jnc.13886
63. Cuajungco MP, Kiselyov K. The mucolipin-1 (TRPML1) ion channel, transmembrane-163
(TMEM163) protein, and lysosomal zinc handling. Front Biosci (Landmark Ed). 2017;22: 1330–1343.
64. Sanchez VB, Ali S, Escobar A, Cuajungco MP. Transmembrane 163 (TMEM163) protein
effluxes zinc. Arch Biochem Biophys. 2019;677: 108166. doi:10.1016/j.abb.2019.108166
65. Burré J, Zimmermann H, Volknandt W. Identification and characterization of SV31, a novel
synaptic vesicle membrane protein and potential transporter. J Neurochem. 2007;103: 276–287.
doi:10.1111/j.1471-4159.2007.04758.x
66. Wang L, Li N-N, Lu Z-J, Li J-Y, Peng J-X, Duan L-R, et al. Association of three candidate genetic
variants in ACMSD/TMEM163, GPNMB and BCKDK /STX1B with sporadic Parkinson's disease in Han
Chinese. Neurosci Lett. 2019;703: 45–48. doi:10.1016/j.neulet.2019.03.019
67. Chang K-H, Chen C-M, Chen Y-C, Fung H-C, Wu Y-R. Polymorphisms of ACMSD-TMEM163,
MCCC1, and BCKDK-STX1B Are Not Associated with Parkinson's Disease in Taiwan. Parkinsons Dis.
2019;2019: 3489638. doi:10.1155/2019/3489638
68. Lauterbach EC. Psychotropic drug effects on gene transcriptomics relevant to Parkinson's
disease. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38: 107–115.
doi:10.1016/j.pnpbp.2012.03.011
69. Chakraborty S, Vellarikkal SK, Sivasubbu S, Roy SS, Tandon N, Bharadwaj D. Role of
Tmem163 in zinc-regulated insulin storage of MIN6 cells: Functional exploration of an Indian type 2
diabetes GWAS associated gene. Biochem Biophys Res Commun. 2019.
doi:10.1016/j.bbrc.2019.11.117
70. Tabassum R, Chauhan G, Dwivedi OP, Mahajan A, Jaiswal A, Kaur I, et al. Genome-wide
association study for type 2 diabetes in Indians identifies a new susceptibility locus at 2q21.
Diabetes. 2013;62: 977–986. doi:10.2337/db12-0406
71. Bai H, Liu H, Suyalatu S, Guo X, Chu S, Chen Y, et al. Association Analysis of Genetic Variants
with Type 2 Diabetes in a Mongolian Population in China. J Diabetes Res. 2015;2015: 613236.
doi:10.1155/2015/613236
72. Foulquier F, Amyere M, Jaeken J, Zeevaert R, Schollen E, Race V, et al. TMEM165 deficiency
causes a congenital disorder of glycosylation. Am J Hum Genet. 2012;91: 15–26.
doi:10.1016/j.ajhg.2012.05.002
73. Demaegd D, Foulquier F, Colinet A-S, Gremillon L, Legrand D, Mariot P, et al. Newly
characterized Golgi-localized family of proteins is involved in calcium and pH homeostasis in yeast
and human cells. Proc Natl Acad Sci USA. 2013;110: 6859–6864. doi:10.1073/pnas.1219871110

74.   Foulquier F, Legrand D. Biometals and glycosylation in humans: Congenital disorders of
glycosylation shed lights into the crucial role of Golgi manganese homeostasis. Biochim Biophys
Acta Gen Subj. 2020;1864: 129674. doi:10.1016/j.bbagen.2020.129674
75.   Stribny J, Thines L, Deschamps A, Goffin P, Morsomme P. The human Golgi protein
TMEM165 transports calcium and manganese in yeast and bacterial cells. J Biol Chem. 2020;295:
3865–3874. doi:10.1074/jbc.RA119.012249
76.   Snyder NA, Palmer MV, Reinhardt TA, Cunningham KW. Milk biosynthesis requires the Golgi
cation exchanger TMEM165. J Biol Chem. 2019;294: 3181–3191. doi:10.1074/jbc.RA118.006270
77.   Reinhardt TA, Lippolis JD, Sacco RE. The Ca(2+)/H(+) antiporter TMEM165 expression,
localization in the developing, lactating and involuting mammary gland parallels the secretory
pathway Ca(2+) ATPase (SPCA1). Biochem Biophys Res Commun. 2014;445: 417–421.
doi:10.1016/j.bbrc.2014.02.020
78.   Lebredonchel E, Houdou M, Potelle S, de Bettignies G, Schulz C, Krzewinski Recchi M-A, et al.
Dissection of TMEM165 function in Golgi glycosylation and its Mn2+ sensitivity. Biochimie.
2019;165: 123–130. doi:10.1016/j.biochi.2019.07.016
79.   Perland E, Lekholm E, Eriksson MM, Bagchi S, Arapi V, Fredriksson R. The Putative SLC
Transporters Mfsd5 and Mfsd11 Are Abundantly Expressed in the Mouse Brain and Have a Potential
Role in Energy Homeostasis. PLoS ONE. 2016;11: e0156912. doi:10.1371/journal.pone.0156912
80.   Lekholm E, Perland E, Eriksson MM, Hellsten SV, Lindberg FA, Rostami J, et al. Putative
Membrane-Bound Transporters MFSD14A and MFSD14B Are Neuronal and Affected by Nutrient
Availability. Front Mol Neurosci. 2017;10: 11. doi:10.3389/fnmol.2017.00011
81.   Perland E, Hellsten SV, Lekholm E, Eriksson MM, Arapi V, Fredriksson R. The Novel
Membrane-Bound Proteins MFSD1 and MFSD3 are Putative SLC Transporters Affected by Altered
Nutrient Intake. J Mol Neurosci. 2017;61: 199–214. doi:10.1007/s12031-016-0867-8
82.   Bagchi S, Perland E, Hosseini K, Lundgren J, Al-Walai N, Kheder S, et al. Probable role for
major facilitator superfamily domain containing 6 (MFSD6) in the brain during variable energy
consumption. Int J Neurosci. 2020;130: 476–489. doi:10.1080/00207454.2019.1694020
83.   Valoskova K, Biebl J, Roblek M, Emtenani S, Gyoergy A, Misova M, et al. A conserved major
facilitator superfamily member orchestrates a subset of O-glycosylation to aid macrophage tissue
invasion. Elife. 2019;8. doi:10.7554/eLife.41801
84.   Landis GN, Bhole D, Tower J. A search for doxycycline-dependent mutations that increase
Drosophila melanogaster life span identifies the VhaSFD, Sugar baby, filamin, fwd and Cctl genes.
Genome Biol. 2003;4: R8. doi:10.1186/gb-2003-4-2-r8
85.   Kim KW, Tang NH, Piggott CA, Andrusiak MG, Park S, Zhu M, et al. Expanded genetic
screening in Caenorhabditis elegans identifies new regulators and an inhibitory role for NAD+ in
axon regeneration. Elife. 2018;7: e39756. doi:10.7554/eLife.39756
86.   Ceder MM, Aggarwal T, Hosseini K, Maturi V, Patil S, Perland E, et al. CG4928 Is Vital for
Renal Function in Fruit Flies and Membrane Potential in Cells: A First In-Depth Characterization of
the Putative Solute Carrier UNC93A. Front Cell Dev Biol. 2020;8: 580291.
doi:10.3389/fcell.2020.580291
87.   Hannes F, Hammond P, Quarrell O, Fryns J-P, Devriendt K, Vermeesch JR. A microdeletion
proximal of the critical deletion region is associated with mild Wolf-Hirschhorn syndrome. Am J
Med Genet A. 2012;158A: 996–1004. doi:10.1002/ajmg.a.35299
88.   Damme M, Brandenstein L, Fehr S, Jankowiak W, Bartsch U, Schweizer M, et al. Gene
disruption of Mfsd8 in mice provides the first animal model for CLN7 disease. Neurobiol Dis.
2014;65: 12–24. doi:10.1016/j.nbd.2014.01.003

89. Siintola E, Topcu M, Aula N, Lohi H, Minassian BA, Paterson AD, et al. The novel neuronal
ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am J Hum Genet.
2007;81: 136–146. doi:10.1086/518902

90. von Kleist L, Ariunbat K, Braren I, Stauber T, Storch S, Danyukova T. A newly generated
neuronal cell model of CLN7 disease reveals aberrant lysosome motility and impaired cell survival.
Mol Genet Metab. 2019;126: 196–205. doi:10.1016/j.ymgme.2018.09.009

91. Li Y, Yang X, Yang J, Wang H, Wei W. An 11-gene-based prognostic signature for uveal
melanoma metastasis based on gene expression and DNA methylation profile. J Cell Biochem. 2018.
doi:10.1002/jcb.28151

92. Nicoletti CF, Pinhel MS, Noronha NY, Jácome A, Crujeiras AB, Nonino CB. Association of
MFSD3 promoter methylation level and weight regain after gastric bypass: Assessment for 3 y after
surgery. Nutrition. 2020;70: 110499. doi:10.1016/j.nut.2019.04.010

93. Rebsamen M, Pochini L, Stasyk T, de Araújo MEG, Galluccio M, Kandasamy RK, et al.
SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1.
Nature. 2015;519: 477–481. doi:10.1038/nature14107

94. Västermark Å, Almén MS, Simmen MW, Fredriksson R, Schiöth HB. Functional specialization
in nucleotide sugar transporters occurred through differentiation of the gene cluster EamA (DUF6)
before the radiation of Viridiplantae. BMC Evol Biol. 2011;11: 123. doi:10.1186/1471-2148-11-123

95. Do DN, Schenkel FS, Miglior F, Zhao X, Ibeagha-Awemu EM. Genome wide association study
identifies novel potential candidate genes for bovine milk cholesterol content. Sci Rep. 2018;8:
13239. doi:10.1038/s41598-018-31427-0

96. Prentice LM, d'Anglemont de Tassigny X, McKinney S, Ruiz de Algara T, Yap D, Turashvili G,
et al. The testosterone-dependent and independent transcriptional networks in the hypothalamus
of Gpr54 and Kiss1 knockout male mice are not fully equivalent. BMC Genomics. 2011;12: 209.
doi:10.1186/1471-2164-12-209

97. Rodriguez PQ, Oddsson A, Ebarasi L, He B, Hultenby K, Wernerson A, et al. Knockdown of
Tmem234 in zebrafish results in proteinuria. Am J Physiol Renal Physiol. 2015;309: F955-966.
doi:10.1152/ajprenal.00525.2014

98. Dean N, Zhang YB, Poster JB. The VRG4 gene is required for GDP-mannose transport into the
lumen of the Golgi in the yeast, Saccharomyces cerevisiae. J Biol Chem. 1997;272: 31908–31914.
doi:10.1074/jbc.272.50.31908

99. Baldwin TC, Handford MG, Yuseff MI, Orellana A, Dupree P. Identification and
characterization of GONST1, a golgi-localized GDP-mannose transporter in Arabidopsis. Plant Cell.
2001;13: 2283–2295. doi:10.1105/tpc.010247

100. Rodríguez A, Gonzalez L, Ko A, Alvarez M, Miao Z, Bhagat Y, et al. Molecular Characterization
of the Lipid Genome-Wide Association Study Signal on Chromosome 18q11.2 Implicates HNF4A-
Mediated Regulation of the TMEM241 Gene. Arterioscler Thromb Vasc Biol. 2016;36: 1350–1355.
doi:10.1161/ATVBAHA.116.307182

101. Trifonov S, Houtani T, Shimizu J-I, Hamada S, Kase M, Maruyama M, et al. GPR155: Gene
organization, multiple mRNA splice variants and expression in mouse central nervous system.
Biochem Biophys Res Commun. 2010;398: 19–25. doi:10.1016/j.bbrc.2010.05.162

102. Wang XC, Liu Z, Jin LH. Anchor negatively regulates BMP signalling to control Drosophila
wing development. Eur J Cell Biol. 2018;97: 308–317. doi:10.1016/j.ejcb.2018.04.007

103. Shimizu D, Kanda M, Tanaka H, Kobayashi D, Tanaka C, Hayashi M, et al. GPR155 Serves as a
Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer. Sci Rep. 2017;7:
42089. doi:10.1038/srep42089

104.   Umeda S, Kanda M, Sugimoto H, Tanaka H, Hayashi M, Yamada S, et al. Downregulation of
GPR155 as a prognostic factor after curative resection of hepatocellular carcinoma. BMC Cancer.
2017;17: 610. doi:10.1186/s12885-017-3629-2
105.   Helenius J, Ng DTW, Marolda CL, Walter P, Valvano MA, Aebi M. Translocation of lipid-linked
oligosaccharides across the ER membrane requires Rft1 protein. Nature. 2002;415: 447–450.
doi:10.1038/415447a
106.   Frank CG, Sanyal S, Rush JS, Waechter CJ, Menon AK. Does Rft1 flip an N-glycan lipid
precursor? Nature. 2008;454: E3-4; discussion E4-5. doi:10.1038/nature07165
107.   Gottier P, Gonzalez-Salgado A, Menon AK, Liu Y-C, Acosta-Serrano A, Bütikofer P. RFT1
Protein Affects Glycosylphosphatidylinositol (GPI) Anchor Glycosylation. J Biol Chem. 2017;292:
1103–1111. doi:10.1074/jbc.M116.758367
108.   Verchère A, Cowton A, Jenni A, Rauch M, Häner R, Graumann J, et al. Complexity of the
eukaryotic dolichol-linked oligosaccharide scramblase suggested by activity correlation profiling
mass spectrometry. Sci Rep. 2021;11: 1411. doi:10.1038/s41598-020-80956-0
109.   Nobre LS, Al-Shahrour F, Dopazo J, Saraiva LM. Exploring the antimicrobial action of a
carbon monoxide-releasing compound through whole-genome transcription profiling of Escherichia
coli. Microbiology (Reading). 2009;155: 813–824. doi:10.1099/mic.0.023911-0
110.   Herzberg M, Kaye IK, Peti W, Wood TK. YdgG (TqsA) controls biofilm formation in
Escherichia coli K-12 through autoinducer 2 transport. J Bacteriol. 2006;188: 587–598.
doi:10.1128/JB.188.2.587-598.2006
111.   Dong P, Wang L, Song N, Yang L, Chen J, Yan M, et al. A UPF0118 family protein with
uncharacterized function from the moderate halophile Halobacillus andaensis represents a novel
class of Na+(Li+)/H+ antiporter. Sci Rep. 2017;7: 45936. doi:10.1038/srep45936
112.   Wang L, Zou Q, Yan M, Wang Y, Guo S, Zhang R, et al. Polar or Charged Residues Located in
Four Highly Conserved Motifs Play a Vital Role in the Function or pH Response of a UPF0118 Family
Na+(Li+)/H+ Antiporter. Front Microbiol. 2020;11: 841. doi:10.3389/fmicb.2020.00841
113.   Shao L, Xu T, Zheng X, Shao D, Zhang H, Chen H, et al. A novel three-TMH Na+/H+ antiporter
and the functional role of its oligomerization. J Mol Biol. 2021;433: 166730.
doi:10.1016/j.jmb.2020.166730
114.   Mesdaghi S, Murphy DL, Sánchez Rodríguez F, Burgos-Mármol JJ, Rigden DJ. In silico
prediction of structure and function for a large family of transmembrane proteins that includes
human Tmem41b. F1000Res. 2020;9: 1395. doi:10.12688/f1000research.27676.2
115.   Morita K, Hama Y, Izume T, Tamura N, Ueno T, Yamashita Y, et al. Genome-wide CRISPR
screen identifies TMEM41B as a gene required for autophagosome formation. J Cell Biol. 2018;217:
3817–3828. doi:10.1083/jcb.201804132
116.   Moretti F, Bergman P, Dodgson S, Marcellin D, Claerr I, Goodwin JM, et al. TMEM41B is a
novel regulator of autophagy and lipid mobilization. EMBO Rep. 2018;19.
doi:10.15252/embr.201845889
117.   Van Alstyne M, Lotti F, Dal Mas A, Area-Gomez E, Pellizzoni L. Stasimon/Tmem41b localizes
to mitochondria-associated ER membranes and is essential for mouse embryonic development.
Biochem Biophys Res Commun. 2018;506: 463–470. doi:10.1016/j.bbrc.2018.10.073
118.   Morita K, Hama Y, Mizushima N. TMEM41B functions with VMP1 in autophagosome
formation. Autophagy. 2019;15: 922–923. doi:10.1080/15548627.2019.1582952
119.   Shoemaker CJ, Huang TQ, Weir NR, Polyakov NJ, Schultz SW, Denic V. CRISPR screening
using an expanded toolkit of autophagy reporters identifies TMEM41B as a novel autophagy factor.
PLoS Biol. 2019;17: e2007044. doi:10.1371/journal.pbio.2007044

120. Schneider WM, Luna JM, Hoffmann H-H, Sánchez-Rivera FJ, Leal AA, Ashbrook AW, et al.
Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. bioRxiv.
2020; 2020.10.07.326462. doi:10.1101/2020.10.07.326462
121. Hoffmann H-H, Schneider WM, Rozen-Gagnon K, Miles LA, Schuster F, Razooky B, et al.
TMEM41B Is a Pan-flavivirus Host Factor. Cell. 2021;184: 133-148.e20.
doi:10.1016/j.cell.2020.12.005
122. Farwell SLN, Kanyi D, Hamel M, Slee JB, Miller EA, Cipolle MD, et al. Heparin Decreases in
Tumor Necrosis Factor α (TNFα)-induced Endothelial Stress Responses Require Transmembrane
Protein 184A and Induction of Dual Specificity Phosphatase 1. J Biol Chem. 2016;291: 5342–5354.
doi:10.1074/jbc.M115.681288
123. Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, et al. The
heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile
acid transporter. J Biol Chem. 2005;280: 6960–6968. doi:10.1074/jbc.M412752200
124. Seward DJ, Koh AS, Boyer JL, Ballatori N. Functional complementation between a novel
mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter,
OSTalpha-OSTbeta. J Biol Chem. 2003;278: 27473–27482. doi:10.1074/jbc.M301106200
125. Wang W, Seward DJ, Li L, Boyer JL, Ballatori N. Expression cloning of two genes that together
mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc Natl Acad Sci
USA. 2001;98: 9431–9436. doi:10.1073/pnas.161099898
126. Rasmussen RN, Christensen KV, Holm R, Nielsen CU. Nfat5 is involved in the hyperosmotic
regulation of Tmem184b: a putative modulator of ibuprofen transport in renal MDCK I cells. FEBS
Open Bio. 2019;9: 1071–1081. doi:10.1002/2211-5463.12630
127. Zhu H, Shang D, Sun M, Choi S, Liu Q, Hao J, et al. X-linked congenital hypertrichosis
syndrome is associated with interchromosomal insertions mediated by a human-specific
palindrome near SOX3. Am J Hum Genet. 2011;88: 819–826. doi:10.1016/j.ajhg.2011.05.004
128. Quamme GA. Molecular identification of ancient and modern mammalian magnesium
transporters. Am J Physiol, Cell Physiol. 2010;298: C407-429. doi:10.1152/ajpcell.00124.2009
129. Stuiver M, Lainez S, Will C, Terryn S, Günzel D, Debaix H, et al. CNNM2, encoding a
basolateral protein required for renal Mg2+ handling, is mutated in dominant hypomagnesemia.
Am J Hum Genet. 2011;88: 333–343. doi:10.1016/j.ajhg.2011.02.005
130. Yamazaki D, Funato Y, Miura J, Sato S, Toyosawa S, Furutani K, et al. Basolateral Mg2+
extrusion via CNNM4 mediates transcellular Mg2+ transport across epithelia: a mouse model. PLoS
Genet. 2013;9: e1003983. doi:10.1371/journal.pgen.1003983
131. Funato Y, Furutani K, Kurachi Y, Miki H. CrossTalk proposal: CNNM proteins are Na+ /Mg2+
exchangers playing a central role in transepithelial Mg2+ (re)absorption. J Physiol. 2018;596: 743–
746. doi:10.1113/JP275248
132. Arjona FJ, de Baaij JHF. CrossTalk opposing view: CNNM proteins are not Na+ /Mg2+
exchangers but Mg2+ transport regulators playing a central role in transepithelial Mg2+
(re)absorption. J Physiol (Lond). 2018;596: 747–750. doi:10.1113/JP275249
133. Funato Y, Furutani K, Kurachi Y, Miki H. Rebuttal from Yosuke Funato, Kazuharu Furutani,
Yoshihisa Kurachi and Hiroaki Miki. J Physiol. 2018;596: 751. doi:10.1113/JP275706
134. Arjona FJ, de Baaij JHF. Rebuttal from Francisco J. Arjona and Jeroen H. F. de Baaij. J Physiol.
2018;596: 753–754. doi:10.1113/JP275705
135. Sponder G, Mastrototaro L, Kurth K, Merolle L, Zhang Z, Abdulhanan N, et al. Human
CNNM2 is not a Mg(2+) transporter per se. Pflugers Arch. 2016;468: 1223–1240.
doi:10.1007/s00424-016-1816-7

136.   Huang Y, Jin F, Funato Y, Xu Z, Zhu W, Wang J, et al. Structural basis for the Mg2+
recognition and regulation of the CorC Mg2+ transporter. Sci Adv. 2021;7: eabe6140.
doi:10.1126/sciadv.abe6140
137.   Hogue DL, Ellison MJ, Young JD, Cass CE. Identification of a novel membrane transporter
associated with intracellular membranes by phenotypic complementation in the yeast
Saccharomyces cerevisiae. J Biol Chem. 1996;271: 9801–9808. doi:10.1074/jbc.271.16.9801
138.   Cabrita MA, Hobman TC, Hogue DL, King KM, Cass CE. Mouse transporter protein, a
membrane protein that regulates cellular multidrug resistance, is localized to lysosomes. Cancer
Res. 1999;59: 4890–4897.
139.   Hogue DL, Kerby L, Ling V. A mammalian lysosomal membrane protein confers multidrug
resistance upon expression in Saccharomyces cerevisiae. J Biol Chem. 1999;274: 12877–12882.
doi:10.1074/jbc.274.18.12877
140.   Tian S, Muneeruddin K, Choi MY, Tao L, Bhuiyan RH, Ohmi Y, et al. Genome-wide CRISPR
screens for Shiga toxins and ricin reveal Golgi proteins critical for glycosylation. PLoS Biol. 2018;16:
e2006951. doi:10.1371/journal.pbio.2006951
141.   Yamaji T, Sekizuka T, Tachida Y, Sakuma C, Morimoto K, Kuroda M, et al. A CRISPR Screen
Identifies LAPTM4A and TM9SF Proteins as Glycolipid-Regulating Factors. iScience. 2019;11: 409–
424. doi:10.1016/j.isci.2018.12.039
142.   Shao G-Z, Zhou R-L, Zhang Q-Y, Zhang Y, Liu J-J, Rui J-A, et al. Molecular cloning and
characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene.
2003;22: 5060–5069. doi:10.1038/sj.onc.1206832
143.   Adra CN, Zhu S, Ko JL, Guillemot JC, Cuervo AM, Kobayashi H, et al. LAPTM5: a novel
lysosomal-associated multispanning membrane protein preferentially expressed in hematopoietic
cells. Genomics. 1996;35: 328–337. doi:10.1006/geno.1996.0364
144.   Grabner A, Brast S, Sucic S, Bierer S, Hirsch B, Pavenstädt H, et al. LAPTM4A interacts with
hOCT2 and regulates its endocytotic recruitment. Cell Mol Life Sci. 2011;68: 4079–4090.
doi:10.1007/s00018-011-0694-6
145.   Milkereit R, Persaud A, Vanoaica L, Guetg A, Verrey F, Rotin D. LAPTM4b recruits the LAT1-
4F2hc Leu transporter to lysosomes and promotes mTORC1 activation. Nat Commun. 2015;6: 7250.
doi:10.1038/ncomms8250
146.   Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, et al. LAPTM4B: a novel cancer-associated gene
motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene.
2010;29: 5785–5795. doi:10.1038/onc.2010.303
147.   Rutsch F, Gailus S, Miousse IR, Suormala T, Sagné C, Toliat MR, et al. Identification of a
putative lysosomal cobalamin exporter altered in the cblF defect of vitamin B12 metabolism. Nat
Genet. 2009;41: 234–239. doi:10.1038/ng.294
148.   Kawaguchi K, Okamoto T, Morita M, Imanaka T. Translocation of the ABC transporter ABCD4
from the endoplasmic reticulum to lysosomes requires the escort protein LMBD1. Sci Rep. 2016;6:
30183. doi:10.1038/srep30183
149.   Kitai K, Kawaguchi K, Tomohiro T, Morita M, So T, Imanaka T. The lysosomal protein ABCD4
can transport vitamin B12 across liposomal membranes in vitro. J Biol Chem. 2021;296: 100654.
doi:10.1016/j.jbc.2021.100654
150.   Wojnar P, Lechner M, Merschak P, Redl B. Molecular cloning of a novel lipocalin-1
interacting human cell membrane receptor using phage display. J Biol Chem. 2001;276: 20206–
20212. doi:10.1074/jbc.M101762200

151. Hesselink RW, Findlay JBC. Expression, characterization and ligand specificity of lipocalin-1 interacting membrane receptor (LIMR). Mol Membr Biol. 2013;30: 327–337. doi:10.3109/09687688.2013.823018

152. Paek J, Kalocsay M, Staus DP, Wingler L, Pascolutti R, Paulo JA, et al. Multidimensional Tracking of GPCR Signaling via Peroxidase-Catalyzed Proximity Labeling. Cell. 2017;169: 338-349.e11. doi:10.1016/j.cell.2017.03.028

153. Lettice LA, Heaney SJH, Purdie LA, Li L, de Beer P, Oostra BA, et al. A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum Mol Genet. 2003;12: 1725–1735. doi:10.1093/hmg/ddg180

154. Ianakiev P, van Baren MJ null, Daly MJ, Toledo SP, Cavalcanti MG, Neto JC, et al. Acheiropodia is caused by a genomic deletion in C7orf2, the human orthologue of the Lmbr1 gene. Am J Hum Genet. 2001;68: 38–45. doi:10.1086/316955

155. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics. 1996;35: 55–65. doi:10.1006/geno.1996.0322

156. Knauer R, Lehle L. The oligosaccharyltransferase complex from Saccharomyces cerevisiae. Isolation of the OST6 gene, its synthetic interaction with OST3, and analysis of the native complex. J Biol Chem. 1999;274: 17249–17256. doi:10.1074/jbc.274.24.17249

157. Knauer R, Lehle L. The oligosaccharyltransferase complex from yeast. Biochim Biophys Acta. 1999;1426: 259–273. doi:10.1016/s0304-4165(98)00128-7

158. Kelleher DJ, Karaoglu D, Mandon EC, Gilmore R. Oligosaccharyltransferase isoforms that contain different catalytic STT3 subunits have distinct enzymatic properties. Mol Cell. 2003;12: 101–111. doi:10.1016/s1097-2765(03)00243-0

159. Cherepanova NA, Shrimal S, Gilmore R. Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins. J Cell Biol. 2014;206: 525–539. doi:10.1083/jcb.201404083

160. Ramírez AS, Kowal J, Locher KP. Cryo-electron microscopy structures of human oligosaccharyltransferase complexes OST-A and OST-B. Science. 2019;366: 1372–1375. doi:10.1126/science.aaz3505

161. Goytain A, Quamme GA. Identification and characterization of a novel mammalian Mg2+ transporter with channel-like properties. BMC Genomics. 2005;6: 48. doi:10.1186/1471-2164-6-48

162. Zhou H, Clapham DE. Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development. Proc Natl Acad Sci USA. 2009;106: 15750–15755. doi:10.1073/pnas.0908332106

163. Li N, Gügel IL, Giavalisco P, Zeisler V, Schreiber L, Soll J, et al. FAX1, a novel membrane protein mediating plastid fatty acid export. PLoS Biol. 2015;13: e1002053. doi:10.1371/journal.pbio.1002053

164. Nilsson R, Schultz IJ, Pierce EL, Soltis KA, Naranuntarat A, Ward DM, et al. Discovery of genes essential for heme biosynthesis through large-scale gene expression analysis. Cell Metab. 2009;10: 119–130. doi:10.1016/j.cmet.2009.06.012

165. Yien YY, Robledo RF, Schultz IJ, Takahashi-Makise N, Gwynn B, Bauer DE, et al. TMEM14C is required for erythroid mitochondrial heme metabolism. J Clin Invest. 2014;124: 4294–4304. doi:10.1172/JCI76979

166. Yien YY, Ringel AR, Paw BH. Mitochondrial transport of protoporphyrinogen IX in erythroid cells. Oncotarget. 2015;6: 20742–20743. doi:10.18632/oncotarget.5124

167.   Klammt C, Maslennikov I, Bayrhuber M, Eichmann C, Vajpai N, Chiu EJC, et al. Facile
backbone structure determination of human membrane proteins by NMR spectroscopy. Nat
Methods. 2012;9: 834–839. doi:10.1038/nmeth.2033
168.   Almagro Armenteros JJ, Salvatore M, Emanuelsson O, Winther O, von Heijne G, Elofsson A,
et al. Detecting sequence signals in targeting peptides using deep learning. Life Sci Alliance. 2019;2.
doi:10.26508/lsa.201900429
169.   Shen D-W, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM. Elevated expression of
TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol.
2010;225: 822–828. doi:10.1002/jcp.22287
170.   Gallenito MJ, Qasim TS, Tutol JN, Prakash V, Dodani SC, Meloni G. A recombinant platform
to characterize the role of transmembrane protein hTMEM205 in Pt(II)-drug resistance and
extrusion. Metallomics. 2020;12: 1542–1554. doi:10.1039/d0mt00114g
171.   Chang J-M, Di Tommaso P, Taly J-F, Notredame C. Accurate multiple sequence alignment of
transmembrane proteins with PSI-Coffee. BMC Bioinformatics. 2012;13 Suppl 4: S1.
doi:10.1186/1471-2105-13-S4-S1
172.   Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, et al. BLAST+:
architecture and applications. BMC Bioinformatics. 2009;10: 421. doi:10.1186/1471-2105-10-421
173.   Sokal RR, Michener CD. A statistical method for evaluating systematic relationships.
University of Kansas Science Bulletin. 1958;38: 1409–1438.
174.   Steinegger M, Meier M, Mirdita M, Vöhringer H, Haunsberger SJ, Söding J. HH-suite3 for fast
remote homology detection and deep protein annotation. BMC Bioinformatics. 2019;20: 473.
doi:10.1186/s12859-019-3019-7
175.   Mirdita M, von den Driesch L, Galiez C, Martin MJ, Söding J, Steinegger M. Uniclust
databases of clustered and deeply annotated protein sequences and alignments. Nucleic Acids Res.
2017;45: D170–D176. doi:10.1093/nar/gkw1081
176.   Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of
high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011;7: 539.
doi:10.1038/msb.2011.75
177.   Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein
sequences. Protein Sci. 2018;27: 135–145. doi:10.1002/pro.3290
178.   Lefort V, Longueville J-E, Gascuel O. SMS: Smart Model Selection in PhyML. Mol Biol Evol.
2017;34: 2422–2424. doi:10.1093/molbev/msx149
179.   Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and
methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0.
Syst Biol. 2010;59: 307–321. doi:10.1093/sysbio/syq010
180.   Anisimova M, Gascuel O. Approximate likelihood-ratio test for branches: A fast, accurate,
and powerful alternative. Syst Biol. 2006;55: 539–552. doi:10.1080/10635150600755453
181.   Chen K, Durand D, Farach-Colton M. NOTUNG: a program for dating gene duplications and
optimizing gene family trees. J Comput Biol. 2000;7: 429–447. doi:10.1089/106652700750050871
1462
1463
1464